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RIASSUNTO 
 
L’RNA interference (RNAi) e’ un meccanismo di silenziamento genico 
sequenza-specifico, conservato durante il processo evolutivo. Il meccanismo di 
silenziamento e’ attivato attraverso la degradazione del mRNA complementare o 
mediante inibizione del processo trascrittivo o di traduzione. Nelle cellule di 
mammifero, l’RNAi viene indotto attraverso l’introduzione o l’espressione 
intracellulare di una molecola di RNA a doppio filamento di 20-22 nucleotidi (chiamata 
short interfering RNA o siRNA) specifica per l’mRNA bersaglio. Nel passato il 
processo di ricombinazione omologa in cellule embrionali era il meccanismo piu’ 
utilizzato per studiare la funzione di un gene di interesse in mammiferi, mediante 
rimozione o sovraespressione del gene stesso. Questo processo risulta pero’ costoso e 
non applicabile a molti organismi, inoltre la delezione del gene in esame puo’ portare a 
processi di compensazione genica o a fenotipi letali. Attualmente l’RNAi e’ 
ampiamente impiegato per determinare la funzione di un gene bersaglio sia in sistemi in 
vitro che in vivo grazie alla sua elevata versatilita’ ed efficienza ed e’ inoltre utilizzato 
nella ricerca farmaceutica per selezionare potenziali bersagli farmacologici.  
Questo progetto di ricerca e’ stato sviluppato allo scopo di investigare 
l’applicabilita’ del meccanismo di RNA interference per il silenziamento genico nel 
sistema nervoso centrale di ratto sia in vitro che in vivo. In particolare, il suo impiego 
nel processo di validazione di un gene d’interesse e’ stato analizzato in relazione al 
recettore purinergico P2X7, un gene potenzialmente coinvolto in patologie psichiatriche 
ed ai due recettori correlati P2X2 e P2X4.  
I recettori purinergici P2X2, P2X4 e P2X7 sono membri della famiglia di 
recettori-canali cationici attivati dall’ATP, permeabili al sodio, potassio e calcio. Questi 
recettori sono espressi in diverse aree cerebrali nei neuroni, dove sono coinvolto nel 
rilascio di neurotransmettitori e nell’attivazione di meccanismi multipli di trasduzione 
del segnale intracellulare. Il recettore P2X7 risulta inoltre espresso in diverse tipologie 
di cellule gliali, in cui e’ coinvolto nella modulazione dei processi neuroinfiammatori e 
nel rilascio di diverse citochine. Studi farmacologici e di associazione genetica 
suggeriscono un ruolo potenziale del recettore P2X7 nei disordini psichiatrici, inclusi la 
depressione unipolare e bipolare. Nel topo l’inibizione dell’mRNA per P2X7, attraverso 
RNA antisenso, induce un comportamento di tipo depressivo. Studi di associazione 
genetica indicano una correlazione tra specifici polimorfismi nel gene codificante il 
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recettore P2X7 e i disordine bipolari (Barden et al., 2004 e 2006). I geni per i recettori 
P2X2 e P2X4 sono all’interno della stessa regione cromosomica di P2X7 associata con 
la depressione e i disordini bipolari. P2X2 e P2X4 sono inoltre espressi in specifiche 
aree cerebrali coinvolte nella depressione, come l’ippocampo, e potrebbero quindi 
svolgere un ruolo nella patofisiologia della depressione. 
Al fine di ottenere la soppressione dei recettori P2X (P2XR), specifiche 
molecole siRNAs sono state disegnate per ogni gene e sono state poi selezionate per 
l’attivita’ mediante trasfezione di colture primarie e linee cellulari esprimenti i geni 
d’interesse. In questo modo la sequenza siRNA piu’ attiva e specifica per ciascun gene 
e’ stata selezionata per la produzione di una cassetta esprimente un “short hairpin RNA” 
o shRNA che porta alla produzione del siRNA di interesse all’interno della cellula. 
Poiche’ lo scopo finale di questo progetto era il silenziamento a lungo termine dei 
recettori P2X nell’ippocampo di ratto, sono stati utilizzati i vettori virali al fine di 
garantire l’espressione prolungata del siRNA nei neuroni e nella glia. Infatti i vettori 
virali impiegati possono infettare il tessuto cerebrale con elevata efficienza e persistono 
episomialmente all’interno della cellula infettata. Per ottenere l’espressione dei siRNAs 
nei neuroni, i vettori virali Adeno-associati (AAV) esprimenti shRNA (AAV-shRNA) 
sono stati prodotti per ciascun gene bersaglio, poiche’ questi vettori possono infettare i 
neuroni con elevata efficienza. Inoltre, vettori Adenovirali 5 (Ad5)-shRNA sono stati 
generati per investigare l’effetto della soppressione di P2X7 nelle cellule gliali. Infatti 
questi vettori virali infettano preferenzialmente la glia. Per selezionare i vettori piu’ 
attivi e specifici in grado di sopprimere l’espressione dei recettori P2X in vivo, i vettori 
virali sono stati inizialmente testati in vitro in colture primarie. I vettori AAV2/6-
shRNA sono stati validati mediante infezione di neuroni ippocampali. Una riduzione 
massima del 80-90% del mRNA dei recettori P2X e’ stata osservata mediante analisi 
TaqMan delle cellulare infettate. E’ stato inoltre identificato un vettore Ad5-shRNA in 
grado di sopprimere del 80% l’espressione del mRNA per P2X7 in astrociti primari di 
ratto. Dati preliminari hanno dimostrato una diminuizione nel profilo funzionale del 
recettore P2X7 in cellule microgliali infettate con il vettore Ad5-shRNA. Questi dati 
hanno indicato una riduzione statisticamente significativa del recettore bersaglio in 
seguito all’infezione con vettori virali esprimenti shRNA in vitro. 
Poiche’ le principali evidenze sperimentali, comprendenti sia studi preclinici che 
genetici, supportano il coinvolgimento del recettore P2X7 nella pato-fisiologia della 
depressione, il lavoro in vivo e’ stato focalizzato su questo gene. Pertanto sia i vettori 
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virali AAV2/6- che Ad5-shRNA-P2X7 sono stati microinfusi in ippocampo di ratto 
utilizzando aghi di vetro. Questa metodica di microiniezione e’ stata selezionata in 
quanto in grado di indurre un livello minimo di danno anatomico nel sito di iniezione. 
In seguito all’infusione dei vettori virali, la soppressione del gene bersaglio e’ stata 
investigata. Nel lavoro in vivo e’ stata dimostrata con successo l’infezione 
rispettivamente di neuroni e cellule gliali in seguito all’iniezione nella regione 
ippocampale del giro dentato (DG) con i vettori virali AAV2/6- e Ad5-shRNA. Inoltre 
una riduzione statisticamente significativa del mRNA per P2X7 e’ stata rilevata 
mediante ibridazione in situ nei campioni iniettati con AAV-P2X7-shRNA rispetto al 
controllo. Una tendenza simile e’ stata riscontrata nei campioni iniettati con vettore 
Ad5-P2X7-shRNA.  
In conclusione, in questo studio sono stati generati e validati vettori virali 
esprimenti shRNA attivi e specifici, in grado di sopprimere l’espressione del gene 
bersaglio in cellule neuronali sia  in vitro che in vivo.  
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1. SUMMARY 
 
RNA interference (RNAi) is an evolutionarily conserved process of sequence-
specific post-transcriptional gene silencing that is triggered by double-stranded short 
interfering RNA (siRNA). At present RNAi has become an important and widely used 
tool for evaluating target gene function both in vitro and in vivo and has been used for 
the screening of potential therapeutic targets in pharmaceutical research.  
This project has been carried out in order to investigate the applicability of RNA 
interference for target gene suppression in the rat central nervous system (CNS) both in 
vitro and in vivo. In particular its application in the process of target validation has been 
evaluated focusing on the purinergic receptor P2X7, a putative target for mood 
disorders and the two related receptors P2X2 and P2X4. 
The purinergic receptor P2X7 together with the P2X2 and P2X4 receptors are 
members of the ATP-gated cation channel family permeable to sodium, potassium and 
calcium. These receptors are expressed in neurons in many regions of the brain where 
they play a role in release of neurotransmitters and activation of multiple intracellular 
signaling pathways. The P2X7 gene is also expressed in several types of glia where it is 
involved in the modulation of neuroinflammatory processes and cytokine release.  
In order to obtain P2X receptor (P2XR) suppression, specific siRNAs were 
designed for each gene and screened for activity by transfecting both primary cells and 
cell lines expressing the target genes. In this way the most active and specific siRNA 
sequence for each gene was selected for the production of a short hairpin RNA (shRNA) 
cassette leading to intracellular production of the targeting siRNA sequence. Viral 
vectors have been used for long term siRNA expression in neurons and glia in the brain 
since these vectors can efficiently transduce brain tissue and persist episomally within 
the infected cell. In order to drive siRNA expression in neuronal cells, Adeno-associated 
viral vectors (AAV) containing an shRNA cassette were produced for each target gene, 
since these vectors can infect neurons with high efficiency. Adenovirus 5 (Ad5)-shRNA 
vectors targeting P2X7 were also produced to investigate the effects of P2X7 
suppression in glia since these viral vectors preferentially infect glia. As a filter to select 
the most active and specific viral vectors that could down-regulate P2XRs in vivo, viral 
vectors were first tested in vitro in primary cells. The AAV2/6-shRNA vectors were 
evaluated by infecting hippocampal neurons. A maximum of 80-90% down-regulation 
of P2XR mRNA was observed by TaqMan analysis of the infected cells. An active 
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Ad5-shRNA vector able to suppress of 80% P2X7 mRNA expression in cultured rat 
astrocytes was also identified. Preliminary data demonstrated a statistically significant 
decrease in P2X7 function in Ad5-shRNA infected microglial cells. These data indicate 
the suppression of target receptor after shRNA viral vector delivery in vitro. 
Both the AAV2/6- and Ad5-shRNA-P2X7 viral vectors were then microinfused 
into rat hippocampus though glass needles. Transduction of neurons and glia 
respectively after infection of the dentate gyrus (DG) region of the hippocampus by 
AAV2/6- and Ad5-shRNA vectors was demonstrated. Moreover a statistically 
significant down-regulation of P2X7 mRNA in AAV-P2X7-shRNA injected DG 
compared to controls was revealed by in situ hybridization. A similar trend was 
observed in the Ad5-P2X7-shRNA injected samples.  
In conclusion, in this study active and specific shRNA-viral vectors able to 
suppress target gene expression in neuronal cells both in vitro and in vivo were 
generated and validated.  
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2. INTRODUCTION 
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2.1 P2X RECEPTOR FAMILY 
 
 
Adenosine 5’-triphosphate (ATP) is one of the first molecules to appear in the 
evolution of biological systems as an energy source and as an essential component of 
nucleic acids. In addition, during the past 25 years, ATP has become accepted as an 
important neurotransmitter/cotrasmitter in both peripheral and central neurons 
(Norenberg and Illes, 2000). The first report about the potent actions of adenine-based 
compounds was published by Drury and Szent-Gyorgyi in 1929, who discovered that 
adenylic acid and adenosine produced sinus bradycardia, complete atrioventricular 
block, a negative inotropic effect on the atrium and cessation of atrial fibrillation in the 
mammalian heart. After more than a decade, Burnstock and his colleagues observed a 
non-adrenergic and non-cholinergic element in the autonomic nervous system and 
proposed that ATP acted as a neurotransmitter and cotrasmitter in the peripheral and 
central nervous systems. This finding was confirmed and extended over the subsequent 
two decades, when ATP-evoked synaptic potentials were recorded in neurons in both 
the central and peripheral systems. Implicit in the concept of purinergic transmission 
was the existence of post-junctional receptors for ATP. In 1978 Burnstock and 
colleagues proposed the subdivision of purinergic receptors into P1 purinoreceptors 
activated by adenosine and P2 purinoreceptors which are preferentially activated by 
ATP and ADP. The implication deriving from the existence of these two families of 
receptors is that, during purinergic transmission, ATP released from nerve terminals 
acts on postsynaptic P2 receptors with an excitatory effect while adenosine generated 
from the extracellular breakdown of ATP by ectonucleotidases, acts largely via P1 
receptors on nerve terminals to inhibit the release of neurotransmitter (Burnstock 1996). 
At the moment there are four subtypes of P1 receptors cloned, namely A1, A2A and 
A2B and A3. All P1 receptors couple to G proteins and present the same typical 7 α-
helix transmembrane domain structure. The P2 receptors are classified in two types 
based on their different molecular structure and different activation times and distance 
of action. Fast excitatory synaptic responses are mediated by P2X receptors comprising 
a family of at least seven receptor subunits (P2X1-7). Slow changes in membrane 
potential is mediated by P2Y receptors, a family of G-protein coupled receptors bearing 
seven transmembrane α-helices activated by purine and/or pyrimidine nucleotides. This 
classification of ATP receptors is in line with the receptors of most of other 
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neurotransmitters such as of acetylcholine (Ach), γ–amino butyric acid (GABA) and 
glutamate, where ligand-gated and G protein-mediated receptor sub-classifications have 
already been established.  
 
2.1.1 ATP function  
 
As previously said, there is now considerable experimental support that ATP 
acts as a cotransmitter with classical neurotransmitters and neuropeptides in the 
peripheral and central nervous systems. ATP participates in non-adrenergic/non-
cholinergic inhibitory neurotransmission in various regions of the gastro-intestinal tract 
with vasopressin intestinal peptide (VIP) and nitric oxide (NO). Both noradrenaline 
(NA) and Ach appear to be cotransmitters with ATP in various peripheral and central 
synaptic terminals (Burnstock, 1996). ATP has also been shown to be a cotransmitter 
with 5-hydroxytryptamine (5-HT), glutamate, dopamine and GABA in the CNS (Illes 
and Ribeiro, 2004). Moreover ATP mediates fast excitatory synaptic transmission in 
some regions of the central nervous system through activation of P2X receptors (Rubio 
and Soto, 2001). 
ATP, mainly through P2Y receptor subtypes, has been shown to regulate ion 
transport in epithelial cells. There is experimental evidence that both P2Y and P2X 
receptors inhibit platelet aggregation, while P2X receptors expressed on smooth muscle 
cells could mediate vasoconstriction (Burnstock, 1996). The involvement of ATP in the 
initiation of pain is mainly mediated by P2X3 receptors which are predominantly 
localized in the subpopulation of small nociceptive sensory neurons in dorsal root 
ganglia. Down-regulation of P2X3 receptors in a model of inflammatory and 
neuropathic pain leads to inhibition of the development of mechanical hyperalgesia as 
well as reversal of established hyperalgesia (Dorn et al., 2004). Purines and pyrimidines 
can both stimulate the progression of cells through the cell cycle and inhibit cell growth, 
depending upon their concentrations, the target cells and the expression of specific P1 
or P2 receptor subtypes. ATP and adenosine have been claimed to play roles in the 
cytological changes and morphogenetic movements occurring during early 
embryogenesis not only as a source of energy, but also as key regulators in 
differentiation and maturation and in the acquisition of highly specialized functions 
(Burnstock 2001).  
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Following ischaemic and traumatic insults purines seem to play a role in limiting 
damage and in favoring repair mechanisms to restore physiological functions. Massive 
amounts of ATP are rapidly released during ischaemia and hypoxia in the 
cardiovascular system and CNS. Some of the responses to ATP released during brain 
injury are neuroprotective but in some circumstances ATP contributes to the 
phatophysiology initiated after trauma (Neary at al., 2003). It also plays a role in long-
term trophic events after ischaemia mainly through activation of glial cells. Multiple P2 
receptor subtypes are expressed by glial cells. Both ATP and adenosine induce 
astroglial cell proliferation and formation of reactive astrocytes. Purinergic receptors are 
also expressed on inflammatory and immune cells. ATP is involved in the development 
of inflammation through a combination of actions such as induced release of cytokines 
from immune cells and histamine from mast cells. In contrast adenosine provokes anti-
inflammatory effects (Burnstock, 2001).  
 
2.1.2 P2Y receptor family 
 
Currently, ten P2Y receptor subtypes have been cloned and display 19–55% 
sequence identity at the protein level. The predicted structure of P2Y receptors includes 
an extracellular N terminus containing several potential N-linked glycosylation sites, 
seven transmembrane spanning regions that assist in forming the ligand binding pocket, 
and an intracellular C terminus that contains several consensus binding/phosphorylation 
sites for protein kinases. A quantitative RT-PCR study indicated the presence of large 
quantities of P2Y1 and P2Y11 mRNA in the human brain when compared with other 
tissues. Like other members of the G-protein coupled receptors superfamily, P2Y 
receptor stimulation leads to activation of heterotrimeric G proteins and their 
dissociation into α and βγ subunits that can then interact with a variety of effector 
proteins. Individual P2Y receptor subtypes have been linked to one or more of the four 
subfamilies of heterotrimeric G proteins (Gs, Gi/o, Gq/11, and G12/13) (Illes and 
Ribeiro, 2004).  
There are several pieces of experimental evidence for the involvement of P2Y 
receptors in ATP-mediated neurotransmitter release both in the peripheral and central 
nervous systems. In particular in cerebral cortical and hippocampal slices it was 
reported that P2Y-like receptor activation inhibits noradrenaline release. Moreover from 
experimental results it was suggested that P2Y2 receptor-types couple to recombinant 
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K+ channels. In addition to these effects, P2Y receptors are also able to potentiate the 
conductance of ionotropic glutamate receptors of the N-methyl-D-aspartate (NMDA)-, 
but not of the a- amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA)-type in 
pyramidal neurons of the rat prefrontal cortex (Illes and Ribeiro, 2004).  
 
2.1.3 P2X receptor family 
 
The P2X family is the most ubiquitous ligand-gated channel family yet cloned and 
these receptor-types have been identified on autonomic nerve endings and on a limited 
population of neurons in the central nervous system (CNS) both on somotodendritic and 
presymaptic sites (North, 2002). P2X receptors are ATP-gated cation-selective channels 
that mediate sodium influx, potassium efflux and, to varying extents, calcium influx, 
leading to depolarization of the cell membrane. Membrane depolarization subsequently 
activates voltage-gated calcium channels, causing accumulation of calcium ions (Ca2+) 
in the cytoplasm. Currently, seven human P2X receptor subunits (P2X1–7) have been 
cloned containing 379 to 595 amino acids and display 30–50% sequence identity at the 
protein level. The predicted structure of the P2X subunits is a transmembrane protein 
with two membrane spanning domains (TM1 and TM2) that are involved in gating the 
ion channel and lining the ion pore, respectively, a large extracellular loop containing 
the ATP binding site, as well as intracellular N and C terminal tails. Native receptors 
may occur as homo- or heteropolymers, potentially of trimeric structure. The P2XRs 
present a low number of conserved aminoacids within the family and with other cationic 
channel families and also a different cationic permeability between different members.  
Within the P2X receptors family, the P2X7 has a distinguished role for several 
reasons. First, this receptor seems to function only in homo-oligomeric form and is 
activated by relatively high concentrations of ATP. Second, this receptor was known 
previously as P2Z receptor, the ‘‘cell death receptor’’. Its prolonged activation elicits 
the opening of a transmembrane pore, permeable to large molecular weight molecules 
up to 800 dalton (Da), leading to cellular death. In addition, in spite of being cloned 
originally from the rat brain, P2X7 receptor was suggested to be expressed 
predominantly on antigen-presenting immune cells and epithelia, functioning as an 
immunomodulatory receptor (Surprenant et al., 1996). Several data confirms that P2X7 
receptor regulates many aspects of immune function in immunocompetent cells. It 
participates in the regulation of the expression and secretion of cytokines and 
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inflammatory mediators and is involved in the direct effectors function of immune cells, 
such as multinuclear giant cell formation and mycobacterium killing (Ferrari et al., 
1997). However, in the past few years the potential role of this receptor in neuronal 
functions was suggested. Although debate has emerged on the cell-type specific 
localization of P2X7 receptor in the nervous system, most data indicate that it is 
involved in the regulation of several neural functions, such as modulation of 
neurotransmitter release, as well as microglial and astroglial activation. Moreover, 
P2X7 receptors have been proposed to play a key role in disorders of the nervous 
system, such as ischemia-reperfusion injury, Alzheimer’s disease, depression and 
anxiety, spinal cord injury and neuropathic pain (Sperlagh et al., 2006). 
 
2.1.3.1 P2XR structure and pharmacology 
 
The first transmembrane spanning region TM1 of these receptors is involved with 
channel gating while the TM2 lines the ion pore. The intracellular N- and C-termini 
possess consensus binding motifs for protein kinases while the large extracellular loop 
presents 10 conserved cysteine residues forming a series of disulfide bridges. The 
hydrophobic region H5 is close to the pore vestibule and is the site for possible 
receptor/channel modulation by cations such as magnesium, calcium, zinc, copper and 
proton ions while the ATP-binding site possibly involves the region of the extracellular 
loop adjacent to TM1 and TM2 (see Fig. 1).  
P2X receptor family members show many pharmacological and functional 
differences. Calcium permeability is high for some subtypes, a property that is likely to 
be functionally important. The kinetics of activation, inactivation and deactivation also 
vary considerably among the different receptors. P2X receptors can be classified into 
rapidly (P2X1, P2X3) and slowly desensitizing types (P2X2, P2X5, P2X6, and P2X7). 
Two P2X2 isoforms differing only in their C terminal regions desensitize at different 
rates. The P2X2(b) isoform is missing a sixty-nine amino acid segment that is present in 
P2X2(a), and desensitizes about 5 fold faster than the longer isoform. It was concluded 
from mutagenesis studies that the rate of desensitization of the P2X receptors is 
controlled by distinct amino acids located in the C-terminus. Moreover, a protein kinase 
C phosphorylation site in the N terminus is necessary for the full expression of slowly 
desensitizing ATP-gated channels (Roberts et al., 2006). 
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All the P2X receptor subunits have consensus sequences for N-linked 
glycosylation (Asn-X-Ser/Thr), and some glycosylation is essential for trafficking to the 
cell surface. In fact, studies of recombinant receptors show that receptors in which any 
two of the three sites are glycosylated appear at the cell surface and are fully functional. 
Receptors in which only one site or no sites are glycosylated are not completely 
functional (North et al., 2002). Heteromultimers as well as homomultimers are involved 
in forming the trimer ion pore. Biochemical evidence suggests that the protein readily 
forms stable trimers and hexamers. Heteromultimers were clearly recognized for 
P2X2/3 in nodose ganglia, P2X4/6 in CNS neurons, P2X1/5 in some blood vessels, 
P2X2/6 in the brainstem and P2X1/4 and P2X1/2. P2X7 does not form heteromultimers 
and P2X6 does not form a functional homomultimer. 
Although detailed signaling mechanisms have not been established for most P2X 
receptor subtypes, it is well known that cytoplasmic Ca2+ triggers a variety of 
intracellular events, in part, through activation of mitogen activated protein kinases 
(MAPKs), protein kinase C (PKC), and calmodulin. For example, ERK1/2 and p38 are 
activated by the P2X7 receptor in astrocytes. Activation of these kinases is required for 
upregulation of monocyte chemoattractant protein. In addition, cytoplasmic Ca2+ is 
generally important for neurotransmitter release via a calmodulin-dependent process 
(Erb et al., 2006). 
The P2X7 subunit is 595 aminoacids long, having 35–40% homology with the 
other six members of the P2X receptor family (Surprenant et al., 1996). Although its 
structure is basically similar to the residual P2X receptor subunits, having two 
transmembrane domains (M1, M2) and a large extracellular loop, its intracellular 
carboxy terminal domain is much longer (239 amino acids) than those of other P2X 
receptor subunits (27–129 amino acids). The long intracellular C-terminal domain has 
been shown to be critical for the pore-forming property of P2X7 receptors while the 
ATP binding site is suggested to be located near a cysteine-rich region of the 
extracellular domain of the receptor, between the M1 and M2 transmembrane regions, 
similarly to other P2X receptor subunits.  
Activation of the P2X7 receptor-gated ion channels leads to two distinct 
responses, depending on the exposure time of the agonist. Following a single brief 
application, a non-selective inward cationic current can be recorded, which is similar to 
inward currents caused by the activation of other P2X receptor subunits, although with 
different deactivation kinetics. Upon repeated or prolonged application the opening of a 
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membrane pore can be detected, which renders the membrane permeable to high 
molecular weight molecules and ions up to 800 Da (Surprenant et al., 1996). Although 
more recently it has been revealed that the permeability of other P2X subunits, such as 
P2X2 and P2X4 can also increase as a function of time, the property of pore dilation is 
generally associated with P2X7 receptors.  
A number of variants of the human P2X7 receptor resulting from alternative 
splicing have been reported, including one that lacks the entire cytoplasmic tail. This 
finding may explain the fact that properties and functions of P2X7 receptors differ 
depending on cell type, as recently shown for microglia and astrocytes. For instance, 
activation of P2X7 receptors on microglia leads to the release of tumor necrosis factor-
alpha (TNFa), while in astrocytes, P2X7 receptor activation does not induce TNFa 
release but instead inhibits the release of this cytokine induced by lipopolysaccharide 
(LPS). Recently, P2X7 receptor gene polymorphisms have been suggested to be 
associated with several diseases but more epidemiological studies are needed to confirm 
these results (Barden et al., 2006; Sperlagh et al., 2006).  
The pharmacological profile of the P2X7 receptor is relatively well established 
and distinguishable from other members of the P2X receptor family and this was useful 
to investigate its function. It has a low affinity for endogenous ATP, which is at least 
one order of magnitude lower than that of other members of the P2X family, while the 
agonist 3’-O-(4-benzoyl-benzoyl)adenosine 5’-triphosphate (BzATP) is at least 10–30-
fold more potent than ATP at the P2X7 receptor. BzATP can bind to other P2X 
receptors with similar potency, in particular P2X1, P2X2 and P2X3, but only at P2X1 
and P2X7 receptors BzATP is substantially more potent than ATP. The divalent cations 
Ca2+, Mg2+, Cu2+ and low pH inhibit current flow through the receptor ion channel 
complex. It is only at the P2X7 receptor where Zn2+ has an inhibitory action. Of various 
antagonists, Brilliant Blue G is a potent, noncompetitive antagonist displaying 
remarkable selectivity towards P2X7 receptors in the nanomolar range while the other 
P2X receptor antagonists, pyridoxal-phosphate-6-azophenyl-20,40-disulphonic acid 
(PPADS) is a potent antagonist at the human P2X7 receptor but less potent at the rat 
receptor (North, 2002). 
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Fig. 1. Model of the P2X1 receptor. The intracellular amino and carboxy termini are associated with 
conserved protein kinase C (PKC) and trafficking motifs, respectively. The channel has two 
transmembrane domains (TM1 and TM2). The large extracellular loop is the site of ATP action; residues 
shown highlighted in red correspond to conserved amino acids that when mutated to alanine resulted in a 
significant decrease in ATP potency. The proposed disulphide bonds are shown and include a highly 
disulphided domain between cysteine (C) residues 117–165. Dotted lines correspond to regions of the 
extracellular domain where their function remains to be determined (Roberts et al., 2006). 
 
2.1.3.2 P2XR localization 
 
Since activation of ATP-gated P2X receptor channels induces a depolarizing 
excitatory input to the neurons bearing them, the understanding of such possible 
excitatory functions of the co-transmitter ATP under physiological conditions requires 
the mapping of P2X receptors in the nervous system. In the last 5 years, the use of 
several techniques such as in situ hybridization by subtype-specific riboprobes, as well 
as immunolabelling, yielded a wealth of data about the distribution of mRNA and 
receptor protein for the seven cloned P2X receptor subunits.  
In the rat nervous system, P2X mRNA or P2X proteins or both have been 
detected throughout the neuraxis. The epithalamic region of the medial habenula, the 
locus coeruleus, the hippocampus, the dorsal horn of the spinal cord, as well as 
sympathetic coeliac ganglia and the myenteric plexus of the enteric nervous system 
express receptor proteins for at least one subtype of P2X subunit. In all of these regions 
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a co-transmitter role of ATP is strongly suggested by electrophysiological evidence. 
The tissue distribution of the seven P2X receptors ranges from abundant to discrete. 
P2X2, P2X4, and P2X6 mRNAs or proteins have been detected throughout the brain 
and spinal cord, as well as in sensory and autonomic ganglia (Norenberg and Illes, 
2000). In rat hippocampus P2X2, P2X4, P2X6 subunits have been localized in 
postsynaptic specializations in CA1 pyramidal cells and Schaffer collateral synapses as 
well as in the granular cell layer (Rubio and Soto, 2001; Sperlagh et al., 2002). P2X1 
receptor, initially believed to be absent in the brain, is expressed in the cerebral cortex, 
striatum, hippocampus and cerebellum, where P2X1 subunit proteins have also been 
detected. Outside the brain, P2X1 is found in the dorsal and ventral horns of the spinal 
cord, sensory ganglia, sensory systems and autonomic sympathetic ganglia. The P2X3 
receptor is believed to mostly occur in capsaicin-sensitive sensory neurons involved in 
nociception and it is mainly restricted to sensory neurons and their termination fields. In 
addition P2X3 was also found in the hypothalamic supraoptic nucleus and in autonomic 
sympathetic ganglia in the adult rat nervous system (Norenberg and Illes, 2000). P2X5 
also showed a restricted localization in the CNS, in particular in the mesencephalic 
nucleus of the trigeminal nerve, while in the peripheral nervous system, P2X5 mRNA, 
P2X5 protein, or both were identified in sensory ganglia. 
 Regarding the P2X7 mRNA distribution, initial Northern blotting studies 
revealed a widespread tissue distribution, showing strong expression in the immune 
system such as the thymus or the spleen, but also in other organs, including the brain, 
spinal cord, skeletal muscle, lung and placenta (Surprenant et al., 1996). With the high 
sensitive RT-PCR analysis, strong mRNA expression for P2X7 receptors was observed 
in several areas of the CNS such as the cortex, hippocampus, brainstem, nucleus 
accumbens and spinal cord of the rat and human brain. Moreover, it was also evident 
that at least at the mRNA level, P2X7 receptors may appear both in neurons and in 
astrocytes or microglial cells (Sperlagh et al., 2006). Immunohistochemical studies 
showed the P2X7 receptor specific immunoreactivity in several areas of the rat brain 
such as amygdala, hippocampus, thalamus, striatum, cerebellum, spinal cord and 
medulla oblongata (Deuchars et al., 2001). Moreover, co-localization studies revealed 
the co-expression of P2X7 receptor with vesicular glutamate transporter 1 (vGLUT1) 
and vesicular glutamate transporter 2 (vGLUT2) as well as with vesicular GABA 
transporter (vGAT) and vesicular acetylcholine transporter (vAChT) in many areas of 
the brain and the spinal cord (Atkinson et al., 2004). In particular, in rat hippocampus 
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P2X7 receptor immunolabeling was detected in the nuclear envelope but also appeared 
at presynaptic nerve terminals in excitatory neurons. Unfortunately, the specificity of 
the most commonly used antibodies has been debated by two recent studies (Kukley et 
al., 2004; Sim et al., 2004), which demonstrate a pseudo-immunoreactivity for P2X7 
receptors in hippocampal sections of P2X7-/- mice. It’s still not clear if this 
immunoreactivity was due to the presence of a neuronal ‘‘P2X7-like’’ protein products 
from alternatively splicing, or the result of the low dilution of the antibody used in these 
studies.  
 Determination of the subcellular localisation of P2X receptors is critical for a 
clearer understanding of their possible roles as a co-transmitter in ATP-mediated 
synaptic transmission. The release of ATP from the axon terminals of a presynaptic 
neuron may activate P2X receptors in the receptive somatodentritic region of a second, 
postsynaptic neuron and in this way contribute to fast excitatory neurotransmission. 
However, released ATP may also act at presynaptic P2X receptors, located either at the 
axon terminal where it is released from or at nearby endings. The activation of such 
presynaptic P2X receptors may lead to facilitation of ongoing action potential-
dependent exocytotic transmitter release through their appreciable Ca2+ permeability. 
Several experimental observations provide strong evidence that different P2X receptors, 
in particular the P2X2, P2X4 and P2X7 subunits are present at some nerve terminals 
and thus may be involved in the modulation of transmitter release (Norenberg and Illes, 
2000). Somatodendritic receptors are usually excitatory (both P2X and P2Y), while 
presynaptic receptors are excitatory (P2X) or inhibitory (P2Y). Furthermore, the same 
neuron may bear a combination of P2X, P2Y and adenosine-sensitive P1 receptors 
which can mediate opposing responses. The final effect depends on the sum of the 
individual components (Fig. 2). 
Regarding peripheral distribution, both P2X1 and P2X2 receptors are expressed 
in smooth muscle and platelets while P2X4 has been detected in testis and colon. P2X5 
is expressed in proliferating cells in skin, gut, bladder and thymus and P2X7 in pancreas 
and skin (Burnstock, 1996).  
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Fig. 2. Purinergic (ATP and adenosine) presynaptic modulation of neurotransmitter release (Cunha and 
Ribeiro, 2000). 
 
2.1.3.3 P2XR involvement in neuronal function 
 
 When defining ATP-mediated responses it is necessary to clearly exclude the 
involvement of adenosine in the presynaptic effects of ATP. This is particularly critical 
in studies performed in the CNS rather than in peripheral preparations, since the 
expression of adenosine A1 receptor mRNA and protein is generally lower in peripheral 
tissues and higher in most CNS regions. The activation of inhibitory A1 receptors 
causes a profound inhibition of synaptic transmission and evoked neurotransmitter 
release through inhibition of calcium influx. The conversion of ATP into adenosine is 
mediated by an ecto-nucleotidase pathway, which is present in most regions and cell 
types in the CNS and present a high catalytic efficiency such that activation of 
adenosine A1 receptors can occur within milliseconds after application of ATP. When 
activated, P2X receptors open within a few milliseconds and allow the non-selective 
passage of cations (Na+, K+, Ca2+) through their channel pore. Hence, measurement of 
rapidly activating cationic inward currents, evoked either by ATP or some of its 
structural analogues in neurons voltage-clamped at a negative membrane potential, 
provides the most direct way to functionally characterize native somatodendritic 
receptors (Cunha and Ribeiro, 2000).  
P2XRs, in particular P2X2, P2X4 and P2X6 receptors seem to be involved in the 
facilitation of excitatory neurotransmission and in the intracellular Ca2+ increase in 
several regions of the brain, in particular in hippocampus. ATP-mediated P2X 
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activation induces fast synaptic currents and an intracellular Ca2+ increase in 
hippocampal CA1 neurons and increases the amplitude of the population spike 
following the stimulation of Schaffer collaterals (Rubio and Soto, 2001, Pankratov et 
al., 2002). Khakh and colleagues demonstrated that endogenously released ATP 
facilitates excitatory transmission onto interneurones by the activation of P2X2 
receptors in the stratum radiatum of the hippocampus (Khakh et al., 2003). The kinetics 
of ATP-mediated excitatory post-synaptic currents (EPSCs), the high Ca2+ permeability 
of P2X receptors and their localization at appropriate sites suggest an important role for 
P2XR in the synaptic plasticity of neuronal cells (Rubio and Soto, 2001). Since the level 
of intracellular Ca2+ can modulate the functional state of several second messengers 
involved in important cellular pathways, the P2XR-mediated Ca2+ modulation suggests 
their involvement in several neuronal functions and hence neurological disorders (Koles 
et al., 2005). Moreover, both in hippocampus and in cerebellum, glutamatergic synapses 
were shown to express several P2XRs, in particular P2X2, P2X4 and P2X6 receptors, 
indicating that P2X receptors may play a significant role at glutamatergic synapses 
(Rubio and Soto, 2001).  
Regarding P2X7, given the low affinity of the endogenous agonist ATP, a crucial 
question in the evaluation of the physiological but also pathological role of P2X7 
receptor is to identify which conditions result in accumulation of extracellular ATP in 
concentrations sufficiently high to activate it. Since ATP is ubiquitous, all metabolically 
active cells of the nervous system such as neurons, astrocytes, endothelial or microglial 
cells are able to synthesize this nucleotide. In addition, ATP is taken up and stored in 
synaptic vesicles of nerve terminals and astrocytes. Physiological neuronal activity 
probably results in a spatially restricted, localized increase in extracellular ATP levels, 
involved in the synaptic transmission and modulation of pre- and postsynaptic functions 
within the synaptic cleft. In this limited space, ATP could reach millimolar 
concentration and activate P2X7 receptors localized near the release site. On the other 
hand, pathological events such as mechanical or metabolic stress, inflammation, cellular 
injury or changes in the ionic environment stimulate ATP release, provoking a more 
widespread activation of the P2X7 receptor. Indeed, several functional data strongly 
support the role of this receptor in information processing in normal and pathological 
state of the nervous system. Several experiments report a role for P2X7 in the 
modulation of glutamate and subsequent GABA release from rat hippocampal slices and 
an increase in intracellular calcium levels in several isolated neurons (Sperlagh et al., 
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2006). Furthermore, the role of P2X7 receptors in these actions has been confirmed by 
the use of P2X7 KO mice, in which ATP evoked GABA and glutamate release is almost 
abolished. In contrast, Armstrong et al. (2002) reported that BzATP elicits long-lasting 
depression of mossy fiber EPSCs underlying the inhibition and not the facilitation of 
glutamate release. Anyway since this result was not confirmed in knock-out animals, it 
was probably the result of BzATP breakdown to Bz-adenosine and the subsequent 
activation of adenosine receptors. Thus, it appears that P2X7 receptors facilitate, rather 
than inhibit transmitter release in the hippocampus (Sperlargh et al., 2002). However, in 
view of the unclear cellular localization of P2X7 receptors in the hippocampus, the 
facilitation of glutamate and GABA release could be mediated by glial cells since this 
P2X7-mediated neurotransmitter modulation was measured in cultured astrocytes. Since 
ATP release from brain slices is highly frequency-dependent, P2X7 receptors may serve 
as molecular sensors of increased neuronal activity and contribute to short- or long-term 
plasticity phenomena, underlying e.g., memory formation. In addition P2X7 receptors 
are activated during pathological conditions, when metabolic distress or cellular damage 
provide an increase in extracellular ATP in the vicinity of P2X7 receptors. 
 
2.1.3.5. P2XR in glia 
 
P2X receptors, including P2X7 receptors, appear to mediate communication 
between glial cells and neurons, between different glial cell types, and within glial 
networks. The main glial cell types of the nervous system are astrocytes, 
oligodendrocytes and microglia. They play an active role in information processing, 
control the homeostasis of the neuronal microenvironment, development and 
differentiation of neural cells and host-defense response. Resident microglia are well 
known as the immune effector cells of the CNS while Schwann cells are involved in the 
immune response in the periphery. To realize their diverse roles, glial cells have to 
communicate with each other and with neurons. P2X7 receptors, besides other ATP 
receptors, seem to play an essential role in these processes. Both P2X7 mRNA and 
protein have been found in astrocytes and in several regions of the brains P2X7 protein 
was co-localized with astrocytic markers as glial fibrillary acid protein (GFAP) 
(Sperlagh et al., 2006). Astroglial P2X7 receptors participate in a wide array of normal 
and pathological functions of the astrocyte network. However, the majority of these 
actions have been described in cultured astrocytes and further experimental work is 
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necessary to prove that P2X7 receptors indeed play such roles in vivo. The primary 
intracellular signal following the activation of P2X7 receptors is a sustained elevation of 
intracellular Ca2+ ([Ca2+]i), caused by Ca2+ influx from the extracellular space through 
the receptor ion channel complex of astrocytes, which is then translated to various 
signal transduction pathways conveying diverse functions (Fumagalli et al., 2003). In 
particular, activation of P2X7 receptors elicits the release of several neurotransmitters as 
glutamate, GABA and purines from cultured astrocytes (Sperlagh et al., 2006). 
Astrocytes also partecipate in neuroinflammatory processes underlying a variety 
of CNS diseases including trauma, ischemia and neurodegeneration. Inflammatory 
stimuli rapidly induce the proliferation and hypertrophy of glial cells, a process called 
reactive gliosis, resulting in the expression and production of cytokines, chemokines 
and other inflammatory mediators (Di Virgilio et al., 2001). P2X7 receptors are 
involved in these pathways and receptor activation promotes the expression of MCP1 
protein, a critical factor in early monocyte infiltration during the neuroinflammatory 
process (Panenka et al., 2001), and other proteins involved in gliosis. Furthermore, it 
increases the phosphoryation of ERK1, ERK2 and p38 MAP kinase, proteins which 
play a role in the commitment of the cells to apoptosis.  
In addition, P2X7 receptor plays an important role in Ca2+ signaling between 
astrocytes and microglial cells (Verderio and Matteoli, 2001). Astrocytes communicate 
by calcium-mediated signaling not only with each other but also with neighboring cells 
including neurons and microglia. The consequence of this is that astrocyte-derived ATP 
activates P2X7 receptors on microglial cells and elicits Ca2+ signals in the microglia, 
which eventually leads to cytolysis (Verderio and Matteoli, 2001). Interestingly P2X7 
receptor-activation in astrocytes usually does not lead to cytolysis, while the same effect 
might cause cellular death in microglia.  
 
2.1.3.6 Pathological role of the P2XR in the nervous system 
 
Since the widespread effects of P2X receptors activation on different aspects of 
neuronal functions and microglial/astroglial activation, their involvement in the 
pathology of CNS and PNS diseases and their possible role as therapeutic targets has 
been suggested. Several experimental data, in particular the demonstration of the 
activity-dependent expression of P2X receptors under pathological conditions and the 
protective role of P2X receptor ligands in animal disease models, support this 
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hypothesis (see for example Dorn et al., 2004 and Vianna et al., 2002). Many of these 
experimental evidences are focused on the P2X7 receptor. Diseases in which P2X7 
receptor may play either a harmful or protective role include neurodegenerative and 
neuroinflammatory diseases, such as ischemia-reperfusion and traumatic injury, 
Alzheimer’s disease, multiple sclerosis, rheumatoid arthritis and retinopathies (Sperlagh 
et al., 2006). The up-regulation of P2X7 receptors has been observed in a number of 
pathological models, including in vivo ischemia, epilepsy (Vianna et al., 2002), 
mechanical injury, neuropathic pain and transgenic models of Alzheimer’s disease. 
Nonetheless, it has not been clarified whether the change in their expression pattern and 
function is a simple adaptive change or plays a more active pathogenetic role. In 
addition, it is also still unknown whether the final result of P2X7 receptor mediated 
actions in neuronal, microglial and/or astroglial cells are protective or harmful (Sperlagh 
et al., 2006).  
Regarding the involvement of P2X receptors in psychiatric disorders, there are 
several experimental evidences for a role of P2X7 in depression and bipolar disorders. 
Reductions of P2X7 receptor level after stressful handling and an increase after 
antidepressant treatment (28 day with paroxetine) were measured in mouse 
hippocampus (Barden et al., 2004). P2X7 mRNA level was found to be down-regulated 
in the temporal cortex of depressed patients in a post mortem study of suicides, non 
suicides and non-medicated patients (Aston et al., 2005). In mice, P2X7 inhibition 
through RNA antisense treatment enhances depressive-like behaviour (Barden, 2004). 
In contrast hippocampal infusion of BzATP leads to improvement of depressive-like 
symptoms, evaluated in the Porsolt test or forced-swimming test. This behavioral assay 
is normally used to test antidepressant drugs. In this assay the animal is forced to swim 
in a water container and, following initial escape-oriented movements, develop an 
immobile floating posture in the water cylinder which reflects the animal's state of 
despair. The total amount of time that the animal demonstrates this immobility 
behavior, which is reduced by antidepressant treatment, is then measured. Recently 
genetic linkage and association studies have identified within chromosome 12q the 
P2X7 gene as a susceptibilty factor for both bipolar and major depressive disorders 
(Barden et al., 2006 and Lucae et al., 2006). Linkage analysis is the attempt to discover 
predisposing genes by identifying sites (polymorphisms) in the genome at which 
sequence variations (alleles) travel with illness within families that have more than one 
affected member. It is a method of locating a disease-associated gene at a specific site 
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on a particular chromosome. Analysis of different single nucleotide polymorphism 
(SNP) markers in the pedigrees used for linkage studies and in case-control populations 
has led to the identification of a non-synonymous SNP lying in exon 13 which show the 
highest association value. This SNP results in an aminoacid substitution (Gln460Arg) in 
the P2X7 intracellular C-terminal domain, which is known to be essential for pore 
formation, intracellular signaling, membrane blebbing and receptor trafficking, and 
indeed leads to alteration of protein functions (Cabrini et al., 2005). More recently, a 
new study has confirmed the allelic associations between bipolar disorder and the above 
SNP marker in a different case-control bipolar collection and shown that a combined 
analysis of data from bipolar patients and mood disorders increase the strength of the 
association (McQuillin et al., 2008). The above data suggest that the observed P2RX7 
polymorphism might play a causal role in the development of both depression and 
bipolar disorder. In addition, in the brain, both microglia and astrocytes are stimulated 
by ATP-induced P2X7 receptor activation, to produce cytokines, chemokines and 
growth factors and it is now well established that the nervous, endocrine, and immune 
systems are closely linked. Several works report increased concentrations of pro-
inflammatory cytokines and their receptors in depressed individuals (Kim et al., 2002). 
Consequently, harmful or sustained inflammatory responses could be associated with 
depressive behavior, and it is possible that the P2X7 receptor plays a key role either 
directly, or mediated by the regenerative loop at glutamatergic synapses (Bennett MR, 
2007). 
Since P2X2 and P2X4 receptors are also expressed in specialized areas of the 
hippocampus and the genes for both receptors are within the region of P2X7 associated 
with depression and bipolar disorder, they too could be involved. Moreover, changes in 
intracellular concentrations of Ca2+ have been observed in patients suffering from mood 
disorders (Wasserman et al., 2004) and these receptors have been shown to play a key 
role in regulation of calcium intracellular levels in brain areas involved in these 
disorders, in particular in the hippocampus. 
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2.2. RNA INTERFERENCE 
 
Post-genomic biomedical research has improved the possibilities to uncover 
disease mechanisms and discover potential target genes relevant to the pathology 
(Mirnics et al., 2000). Microarray-based genomic analyses permit measuring the 
complete expression patterns in pathological samples and proteomic platforms enable 
the identification of proteins with altered expression in a disease state. These techniques 
permit the systematic identification of a large number of targets with patho-
physiological relevance and their involvement in the disease needs to be validated in 
vivo. Pharmacological, immunological and genetic manipulation tools are available for 
in vivo gene validation (Fig. 3). Pharmacological tools are characterized by the use of 
specific molecules able to directly activate (e.g., agonists, positive allosteric 
modulators) or inhibit (e.g., antagonists, negative allosteric modulators) the protein 
product of the gene and provide a rapid means of in vivo target validation. Antibodies 
can be used as immunological tools to inhibit the target protein and validate its function 
in vivo (Salfeld, 2004). These tools have the advantage of rapidly revealing a target-
based phenotype but the disadvantage of the difficulty and time-consuming process of 
finding small molecule compounds or generating antibodies that are selective for the 
target protein. In addition, the gene product must be identified in order to employ these 
tools and often many of the resulting genes from microarray or genetic studies are not 
functionally characterized or are not full-length sequences but just expressed sequence 
tags (ESTs). The genetic approach requires the production of mutants by homologous 
recombination in embryonic stem cells (ES) such that the gene of interest is either 
stably over-expressed or knocked out in animals. This approach is far more selective 
than pharmacological or immunological manipulation but a major disadvantage is the 
restricted feasibility of homologous recombination in rodent ES cells. This is further 
complicated by the phenotypic differences observed among different strains following 
mutation of the same gene. Other disadvantages of this approach are the enormous 
amount of time involved in generating stably expressing mutant off-springs, the 
impossibility to phenotype genes critically involved in the early developmental stages 
and genetic compensation and developmental adaptations that may mask a clear 
phenotype. These last disadvantages have been addressed by the use of inducible 
transgenic animals. 
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Fig. 3. Tools for in vivo target validation (Thakker et al., 2006). 
 
Gene expression in somatic cells can be manipulated using antisense or 
ribozymes. Ribozymes are RNA molecules that bind the target mRNA in a sequence-
specific manner and catalyse the cleavage of the mRNA. Antisense technology uses 
either DNA or RNA molecules complementary to sequences on the target mRNA, 
inhibiting protein production. These techniques were successful in some situations but 
difficult to apply universally. 
In this context the advent of siRNA-mediated gene knockdown has allowed an 
inexpensive and rapid analysis of gene function in mammals. At present RNAi has 
become an important and widely used tool for evaluating target function both in vitro 
and in vivo and has been used for the screening of potential therapeutic targets in 
pharmaceutical research. The advantages of RNAi over other techniques include its high 
specificity (in some cases, a single point mutation can abolish a silencing effect), 
versatility (interfering RNA can be designed virtually against any gene), and efficiency 
(in many cases, genes can be silenced by over 90%). Moreover the therapeutic 
application of RNAi is beginning to be explored. Recently phase I clinical trials were 
initiated to treat two different pathologies, Respiratory Syncytial Virus (RSV) infection 
and age-related macular degeneration (AMD). These are the first human trials testing 
the efficacy of this novel approach (Li et al., 2006). 
 
2.2.1 RNA interference discovery 
 
RNA interference (RNAi) is defined as the process by which double-stranded 
(ds)RNA silences sequence specific gene expression, either by inducing the degradation 
of complementary mRNA or by inhibiting translation. This mechanism was found and 
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described for the first time by Fire and colleagues in 1998 (Fire et al., 1998), who found 
that injection of dsRNA into Caenorhabditis elegans lead to target gene suppression 
dependent on hybridization between the injected RNA and endogenous messenger RNA 
transcripts. The first silencing phenomena were described in plants (post-transcriptional 
gene silencing or PTGS) and fungi (quelling) (see Sharp, 1999). Evidence of the 
existence of RNA-silencing pathways first came from experiments in plants. Rich 
Jorgensen and colleagues engineered petunias carrying transgenic copies of the gene 
encoding chalcone synthase, the limiting enzyme in the synthesis of the flower’s purple 
pigment. Their intent was to generate more intensely purple flowers, but often their 
efforts yielded plants with dramatic pigmentation patterns comprising tissue in which 
chalcone synthase was produced, flanking tissue in which both the transgenic and 
endogenous chalcone synthase genes were mysteriously turned off. They defined this 
phenomenon “co-suppression” (Napoli et al., 1990). Studies in Drosophila 
melanogaster similarly reported that the more transgenic copies of alcohol 
dehydrogenase (Adh) that were engineered into flies, the less Adh mRNA was actually 
produced. In the mid-1990s, David Baulcombe’s laboratory discovered that plant 
viruses could also trigger sequence-specific silencing and they showed that this viral-
induced gene silencing (VIGS) was mechanistically related to the silencing triggered by 
transgenes. The link between the two silencing pathways was that both required 
transcription of RNA from the trigger locus, implicating RNA as the initiator of 
silencing (Ratcliff et al., 1997). Specifically, it was suggested that dsRNA, formed by 
two RNA molecules annealing or one folding back on itself, might be recognized by 
plant cells as an activator for the sequence specific silencing of genes. Subsequently 
Fire and colleagues proved this to be true for RNAi in animals, and other researchers 
subsequently showed the same for plants.  
More recently viral defence has been proposed to be the primary function of 
RNAi in both plants and animals. In fact the presence of similar RNA interference 
machinery in several organisms has raised the hypothesis of an evolutionary 
development of RNAi as a defence system against RNA virus, transposons and other 
external nucleic acids that can lead to insertional mutagenesis, probably before plants 
and animals diverged. The development of PTGS and other silencing mechanisms, such 
as protection from DNA or RNA viral infection, is supported by the presence of counter 
strategies in many DNA or RNA viruses. Several plant viruses present genes encoding 
suppressor proteins, which block the development of the PTGS state. In any case the 
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mechanism of suppression of the dsRNA-induced gene silencing by viral proteins 
remains to be investigated. 
Initially RNA interference was thought not to be useful for targeted gene silencing 
in mammals, because dsRNA molecules that are longer than 30 base pairs (bp) 
stimulate the antiviral interferon pathway, resulting in cell death. This process is caused 
by inhibition of protein synthesis through protein kinase R-mediated phosphorylation of 
the translational initiation factor eIF2 and non-specific mRNA degradation via the 2’-5’ 
oligoadenylate synthase-RNase L pathway. Tuschl and colleagues in their studies of 
RNAi processes in Drosophila melanogaster embryo extracts showed that long dsRNA 
substrates could be cleaved into short interfering dsRNA species (siRNAs) of ~22 
nucleotides (nt), able to anneal to the target mRNA driving its degradation. They also 
showed that the introduction of a chemically synthesized 21-22nt siRNA to these 
extracts facilitated the degradation of the homologous target mammalian genes 
(Elbashir et al., 2001), evading in this way the interferon response. Another technical 
advance came from the demonstration that siRNAs could be endogenously expressed in 
the form of short hairpin RNAs (shRNAs) by a plasmid transfected into a cell. The 
plasmid contains an shRNA cassette with a promoter that drives the transcription of a 
fold-back stem-loop RNA structure. This shRNA is then recognized by the RNAi 
machinery and is therefore able to induce target-gene silencing in mammalian cells.  
In addition to its power as a tool for gene silencing in biology, RNAi is thought to 
be an important system of gene expression regulation due to the discovery of micro 
RNAs (miRNAs). miRNAs have been cloned from various organism and cells (the first 
identified was lin-4 from C. Elegans) and are short RNA species (~22nt) produced by 
cleavage of longer (~70nt) endogenous precursors with imperfect hairpin RNA 
structure. miRNAs have been showed to be developmentally regulated and to share 
much of the same machinery of siRNA-induced gene silencing. Recently several 
miRNA genes have been discovered in mammals, confirming the prospect that the 
cellular machinery necessary for RNAi in mammalian cells is linked to normal process 
of gene regulation (Grosshans and Slack, 2002), mainly during development. 
 
2.2.2 The mechanism of gene silencing by RNAi 
 
RNAi can be triggered by various types of molecules, including long dsRNAs and 
plasmid-based shRNAs. These molecules are processed in the cytosol by the 
ribonuclease-III activity of the evolutionary conserved Dicer enzyme to generate 21-
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22nt siRNAs (initiation step). The siRNAs are characterized by 2-3-nt 3’ overhangs and 
5’-phospate and 3’-hydroxyl groups. The Dicer enzyme is part of class III enzyme 
family characterized by the presence of two RNaseIII catalytic domains, a helicase 
domain and a PAZ (Piwi/Argonaute/Zwille) domain. The siRNAs produced are then 
incorporated into a protein complex, known as the RNA-induced silencing complex 
(RISC) mediating the effector step. RISC uses an ATP-dependent RNA-helicase 
activity to unwind the duplex siRNA into single stranded siRNA. The antisense strand 
of the duplex guides the RISC complex to the homologous mRNA, where the RISC-
associated RNaseH enzyme Argonaute 2 (Slicer) cleaves the target mRNA at a single 
site in the centre of the duplex region, 10nt from the 5’ end of siRNA. This results in the 
silencing of the target gene through a reduction in the level of target mRNA and 
subsequently of the protein. As previously described RISC is characterized by a multi-
protein complex that can vary in composition and size. Central to this complex is a 
member of the Argonaute family, a gene family conserved in most eukaryotic and 
several prokaryotic genomes. RISC complex may also facilitate the modification of 
chromatin through recruitment of enzymes responsible for chromatin modification (e.g., 
methylation) as well as other proteins, such that RNAi can induce silencing at the 
transcriptional level (Verdel et al., 2004).  
In the case of endogenous hairpin micro RNAs, the mechanism of RNAi starts 
with nuclear transcription of long primary miRNA precursor with a stem-loop structures 
containing the miRNAs. The RNase III enzyme Drosha cleaves this structure away from 
the miRNA precursor to generate pre-miRNA intermediates. These pre-miRNAs are 
transported from the nucleus to the cytoplasm by the nuclear export factor, Exportin-5, 
where the pre-miRNAs are cleaved by Dicer to generate miRNAs which are then 
incorporated in the miRNA-protein complex (miRNP). The miRNAs are believed to 
suppress the expression of partially complementary target mRNAs by translation 
inhibition rather than mRNA degradation: anyway dsRNA, shRNA and miRNA elicit 
RNAi through common biochemical pathways (Fig. 4). The translational inhibition 
mechanism droved by miRNAs has not been completely elucidated: one recent 
hypothesis is that microRNA/RISC complex blocks cap-dependent initiation of 
translation. Drosha and Dicer activity is supported by dsRNA binding domain proteins 
(dsRBD) which acts as co-factors helping for example strand specific incorporation of 
the siRNA. Reassuming it is possible to identify three different mechanisms of 
silencing: the cytoplasmatic degradation of target mRNA induced by siRNAs (produced 
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from long dsRNAs or shRNAs), miRNA-induced translation inhibition of partially 
complementary mRNAs and nuclear transcription blockage through chromatin 
modification. 
 
 
Fig. 4. The RNA interference pathway. a. Short interfering RNA. b. Long double-stranded RNA. c. The 
microRNA pathway.  
 
2.2.3 Designing siRNA 
 
Target gene silencing can be induced by the introduction of siRNA into the cell or 
siRNA production inside the cell. As shown by Tuschl and colleagues, synthetic 
siRNAs of 21-22nt can effectively suppress target gene expression in mammalian cells. 
In order to achieve efficient and specific gene silencing, it is important to optimize 
design, identification and delivery of effective siRNAs, where effective is defined as 
>90% specific reduction in protein levels when a siRNA is used at 1-20nM. Several 
groups have proposed basic empirical guidelines for designing effective siRNAs based 
on the understanding of RNAi biochemistry and miRNA function. The criteria for 
siRNA design are thermodynamic and structural parameters like a low to medium 
guanosine-cytosine content (30-50%), low internal stability at the 5’antisense strand and 
high internal stability at the 3’sense strand to facilitate interaction with RISC. Base 
preference at specific positions in the sense strand is required to promote antisense-
strand selection by RISC and efficient unwinding. Stringent homology searches are 
 33
needed to minimize potential non-specific gene silencing. Moreover, from studies of 
RISC complex structure, an effective siRNA (or microRNA) sequence needs to begin 
with an adenosine or uridine and have a mismatched guanosine or cytosine at the 5’ 
end. The application of these rules significantly improved effective siRNA selection. 
The same rules can be applied to plasmid-encoded shRNAs. The secondary structures of 
the target mRNA which might limit the accessibility of the siRNAs also have to be 
considered. In line with this, the application of an algorithm that can predict the 
secondary structure of mRNA from its primary sequence helps find an effective siRNA. 
At the moment several commercial algorithms, such as these available on the Ambion 
and Dharmacon web site, have been designed that predict the most successful siRNA 
for a particular target gene. Moreover a pool of different siRNAs targeting the same 
gene can be used, which lowers the amount of a single siRNA required to achieve 
successful gene suppression, enhancing RNAi specificity.  
 
2.2.4 Delivery of siRNA  
 
In vitro delivery 
For RNAi to be effective and elicit gene silencing, the double-stranded RNA must 
be delivered to the target cell and in some occasions this can be quite difficult. siRNA 
introduction intracellularly could be requested for gene function studies in vitro or to 
select the active siRNA sequence for in vivo work. Synthetic siRNAs can be delivered 
to mammalian cells by viral and non-viral methods.  
Among the non-viral methods, injection of pure, unmodified siRNA or chemically 
stabilized and modified RNA has been successfully developed. Moreover the 
encapsulation of siRNA into microparticles or liposomes, the binding of siRNA to 
cationic or other particulate carriers and the electroporation of siRNAs into cells have 
been recently used for many targets and for several cell types. Several lipophilic agents 
are commercially available for the delivery of siRNAs into cells, with different 
formulations optimized for each cell type. The limit of this system is the transient nature 
of the RNAi response and in some cases, the lipid-mediated cellular toxicity, which can 
be a major hurdle for phenotype identification following target gene suppression. 
Chemical modification of siRNA, in particular on the phosphate backbone, can facilitate 
siRNA entry into the cell but even if modified, siRNA can be rapidly degraded by 
nucleases.  
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These limitations can be overcome by the use of plasmids that harbour siRNA 
expression cassettes, providing continuous expression of shRNAs into the cell. The 
shRNA is predicted to contain a perfectly double-stranded stem of 19-29 bp, 
characterized by the antisense strand, which is identical to the target sequence in the 
mRNA and the complementary sense strand. The 2 strands of the stem are connected by 
a loop of 6-9 bases. The loop of the hairpin can be digested in the cytosol by the RNAi 
enzymatic machinery to form the active siRNA. This will enter in the enzymatic RISC 
complex in order to be unwound and annealed with the target mRNA driving its 
degradation. In general, chemically synthesized siRNAs that are effective in gene 
silencing are also effective when expressed from an shRNA. However the length of the 
stem and the size and sequence of the loop seem to affect the silencing efficiency. Stem 
lengths of 19 to 29 nt have been described, demonstrating that the stem size is not the 
limiting parameter. On the contrary, the dimension and sequence of the loop seems to 
be critical. In a direct comparison of loop sequence and size, the 9 nt loop sequence 5’-
UUCAAGAGA-3’, also called the Brummelkamp loop, was the most efficient silencer 
using a constant 19 nt duplex (Brummelkamp et al., 2002). This loop is frequently used 
by researchers. Another important parameter in the design of the shRNA vector is the 
promoter. RNA polymerase III (pol III) promoters, mainly U6 and H1 small nuclear 
RNA (snRNA) promoters, are widely used to drive shRNA expression, because they are 
active in almost all cell types and efficiently direct the synthesis of small non-coding 
RNA with well defined ends. The U6 promoter requires a guanosine at the +1 position, 
while the H1 promoter is much more permissive. RNA pol III efficiently recognizes a 
cluster of 4 or more thymidine residues as a termination site. Transfer RNA (tRNA) 
promoters and RNA pol II-based cytomegalovirus (CMV) promoters have also been 
used. Generally, a single promoter drives the expression of the shRNA, which is 
subsequently processed by Dicer into siRNA, but it is also possible to use different 
promoters to drive the expression of the sense and antisense strands. 
 The use of plasmid shRNA vectors in vitro might be ineffective when the target 
cells are difficult to be transfected, such as freshly isolated primary cells, neuronal cells 
and stem cells. In order to overcome this problem, viral vector expressing shRNA 
cassettes can be used. The various viral vectors ensure broad tropism and efficient 
transduction of both transformed and primary mammalian cells. These will be described 
in more detail later. Briefly, the five types of viral vectors that are mainly used for 
RNAi include retrovirus, lentivirus, adenovirus, adeno-associated-virus (AAV) and 
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baculovirus. To achieve stable integration of the shRNA-expression cassette into the 
host genome, lentiviral vectors, retrovirus vectors based on the Moloney murine 
leukaemia virus (MoMuLV) or the murine-stem cell virus (MSCV) can be used. A 
disadvantage of lentiviruses and retroviruses is that they can integrate into the host 
genome causing insertional mutagenesis. To avoid integration, adenovirus or adeno-
associated viral vectors are preferred. 
In vivo delivery  
In vivo RNAi can be useful to elucidate gene function or to achieve therapeutic 
gene silencing. Several methods are available for RNAi in the live animals such as non-
viral local or systemic delivery of siRNA, viral or plasmid delivery of shRNA and the 
constitutive or inducible expression of shRNA in transgenic animals.  
Non-viral delivery of siRNA in vivo is challenging since small RNA molecules 
like siRNAs are relatively unstable in the extracellular and intracellular environment 
due to the presence of RNA degrading enzymes (RNAses) in serum. Even if chemically 
modified to increase stability, when systematically administered they are rapidly 
excreted or diluted. A large amount of siRNA is therefore necessary to obtain an 
effective silencing. Actually few papers have reported successful silencing of genes in 
vivo using naked siRNAs or shRNA encoding plasmid DNA (Ocker et al., 2005). The 
duration of siRNA activity in vivo and any possible therapeutic effect will depend on its 
stability in serum. Double stranded RNA is more stable than single strand RNA but it 
will still be degraded within a few hours. Chemical modifications which increase 
stability of siRNA molecules without affecting RNA interference have been 
investigated. Ideally, chemical modifications could also increase thermal stability, 
cellular tropism, silencing activity and pharmacokinetic properties of the siRNA. 
Locked nucleic acid (LNA) residues that increase stability of oligonucleotides have 
been used successfully to enhance the effect of antisense RNA and ribozyme RNA (Li 
et al., 2006). Another way to chemically stabilize RNA molecules is via 
phosphothioates (PS) in which phospho-sulfur replace phosphodiester linkages in the 
sugar backbone of the RNA. PS linkages increase the half-life of oligonucleotides in 
vivo and were used with antisense nucleotides in several clinical trials to increase 
stability (Crooke, 2000). Other reported chemical alterations include modifications of 
residues added at the 2' position of the ribose since the 2'OH group is not required for 
silencing in siRNA. Several cationic lipids and polymers have been developed to deliver 
normal or modified siRNAs. The most popular envelopes include liposomes and other 
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nanoparticles. Liposomes made of a mixture of cationic and neutral lipids have been 
formulated, covered with a hydrophilic polyethylene glycol (PEG)-lipid which 
facilitates formulation and administration in the aqueous phase (Li et al., 2006). In an 
attempt to confer more specific tissue tropism to liposome-carried RNAi, some groups 
established methods to increase affinity for defined cell types using either ligands for 
specific receptors or antibodies against cell surface markers. Successful applications 
have been obtained either by local application to organs such as brain, lung, muscle and 
tumors or systemically by intravenous or intraperitoneal administration (Xie et al., 
2006; Li et al., 2006). 
Another approach for interfering with gene expression in vivo is shRNA-mediated 
transgenic RNAi that, through electroporation of the shRNA expression vector into 
mouse ES cells, offers a prolonged, stable, loss-of-function phenotype in vivo. Stable 
integrants demonstrating significant gene knockdown are then injected into blastocysts. 
With this method, it has been demonstrated stable passage of the RNAi-induced gene 
knockdown from the ES cells to adult mice by germline transmission of the shRNA-
expressing vector in the F1 progeny (Carmell et al., 2003). Since lentiviral vectors can 
infect mouse ES cells and are resistant to proviral silencing during development, they 
have been used for transducing ES cells with shRNA-expressing vectors (Rubinson et 
al., 2003). Alternative methods have been developed to generate transgenic RNAi 
animals, for which homologous recombination is not possible due to the lack of ES cells 
such as injection of shRNA constructs into the pronuclei of mouse or rat fertilized eggs. 
However, similar to traditional knockouts, the constitutive and widespread gene 
knockdown in the whole animal presents serious limitations to the use of transgenic 
RNAi animals. As a solution, the Cre–loxP recombination system has been recently 
employed to produce an inducible and cell or tissue-specific expression of shRNAs. In 
this system, the shRNA-expression vector is modified in order to incorporate a specific 
sequence that prevents transcription from the vector, flanked by loxP sites. These sites 
are recognized by the Cre recombinase, therefore only a Cre-mediated recombination 
event is able to restore the original open reading frame of the vector. The use of 
inducible Cre expression systems, such as tetracycline or tamoxifen, along with 
transgenic RNAi, represents a systematic evaluation of organ or tissue-specific gene 
suppression (Ventura et al., 2004).  
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2.2.5 Viral vectors as delivery agents 
 
Viruses are naturally evolved vehicles to efficiently transfer genes into host cells. 
This property makes them ideal for engineering viral vectors for the delivery of genes. 
Viral vectors are commonly used in a wide number of applications, such as gene 
therapy to restore normal function or to treat diseases such as cancer. They are 
employed for gene expression modulation to investigate the function of a target gene or 
to confirm the involvement of a gene in a disease mechanism as part of the target 
validation process. The viral vectors normally used in laboratory or clinical research are 
based on RNA or DNA viruses with different genomic structures and host ranges and 
are characterized by an ability to efficiently deliver and express foreign sequences into 
host cells. These are mainly retroviruses, adenoviruses, adeno-associated viruses, 
herpesviruses and poxviruses. Retroviruses are most widely used since these viruses 
have high gene transfer efficiency and mediate high expression of target genes. More 
recently members of the DNA virus family, such as adenovirus-, adeno-associated virus 
and herpes virus (HSV) have also been used for efficient gene delivery. Moreover, 
numerous new viral vectors are being developed based on vaccinia virus, human 
cytomegalovirus, Epstein-Barr virus and others (Walther and Stein, 2000). From the 
beginning of the development and utilization of viral vectors, efforts have been made to 
increase infection, viral targeting, cell-type specific expression, duration of expression 
and safety, to develop efficient and safe RNA- and DNA-viral vectors. This is 
particularly important when using viral vectors for in vivo applications, which require 
limited toxicity derived from viral infection, immuno-responses towards viral antigens 
or potential homologous viral recombination.  
Retroviral vectors are derived from RNA viruses which reverse-transcribe their 
RNA viral genome into double stranded DNA, which is then stably inserted into the 
host DNA. Members of this class of virus are the murine leukaemia virus (MuLV) and 
lentivirus. These viruses are characterized by three structural genes, gag, pol and env, 
flanked by viral long terminal repeats (LTR), which are responsible for the regulation 
and expression of the viral genome and the integration of the pro-virus into host DNA. 
Removal of structural genes and the packaging signal (psi-site) are performed to 
produce safe and efficient recombinant viral vectors. Helper cells are required to replace 
the viral structural genes. The advantages of these viral vectors are determined by their 
characteristics of stable integration into the host genome, generation of viral titers 
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sufficient for efficient gene transfer, infection of a broad variety of target cell types and 
the ability to carry foreign genes of reasonable size (≤8 kilobases, kb). Thanks to these 
properties, they lead to persistent expression of the transgene in the transduced cells and 
their progeny cells with a high level of expression, which is essential to obtain a 
therapeutic effect or modify a phenotype. For efficient gene expression the transgene is 
placed in opposite orientation in relation to the viral LTR. It is possible to insert an 
entire gene cassette of a functional gene, including its own regulatory unit. These 
vectors are characterized by several disadvantages including the instability of some 
retroviral vectors, possible insertional mutagenesis by random viral integration into host 
genome and the requirement of cell division for the infection of MuLV-derived vectors. 
Nonetheless, retroviral-derived vectors and in particular those based on Moloney 
MuLV, are currently used in vivo. Among the lentiviral family the most widely used for 
the production of viral vectors is the human immunodeficiency virus (HIV) which can 
infect both dividing and non dividing cells. 
DNA viruses contain a single- or double-stranded DNA viral genome. The most 
predominant viruses used are the Adenovirus, AAV and HSV thanks to their large 
packaging capacities, broad range of target cell tropism and efficient infection and gene 
transfer. Adenoviruses are non-enveloped DNA viruses carrying linear double-stranded 
DNA of about 35kb. There are at least 49 serotypes known, which can be further 
classified by haemagglutination properties. The most characterized, which is used for 
engineering work, are the adenovirus type 2 (Ad2) and type 5 (Ad5), since these are not 
associated with severe diseases in humans and are therefore suitable for in vivo use. 
Adenoviral genome is modified by deleting the early gene 1 (E1A), essential for virus 
replication, to create replication incompetent vectors and to provide sufficient space to 
carry exogenous genes. Partial deletions of E1B and E3 genes are also made to create 
more space for gene insertion, producing vectors with packaging capacities of 7 to 8kb. 
Helper cells, which provide the essential E1A protein in trans for efficient viral 
encapsulation are needed for the production of infectious viral particles. The human 
embryonic kidney cell line (HEK) 293 with the E1A gene stably inserted is normally 
used for generation of recombinant viral stock since these cells are easy to transfect and 
produce high virus titres. Viral titres of 1010 colony forming units (cfu) /ml can be 
achieved using this system, which is a great advantage over retroviral vectors, since 
these titres ensure efficient in vivo gene transfer. Furthermore, adenoviruses have a 
broad cell tropism and can infect non-dividing cells. On the other hand, they allow only 
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a transient expression of a transgene, since they persist in infected cells as an episome 
and expression of the E2 viral protein provokes inflammatory reactions and toxicities 
that limit repeated application of the viral vectors. To prevent immunogenic reactions, 
second generation vectors were established with lack of E2A functions in addition to a 
mutation or deletion of the viral E4 gene (Morsy and Caskey, 1999). These vectors 
require helper cells which can provide the E4 function required for transcription 
regulation, transition from early to late viral gene expression, mRNA transport, viral 
DNA replication, shut-off of host gene expression and assembly of the virion. More 
recently defective adenoviral vectors were created in which all viral coding regions 
were removed, leaving only the inverted terminal repeats (ITR), the transgene and psi 
packaging sequences in these vectors (Kochanek et al., 1996). The advantage of such 
vectors is that they are less immunogenic and produce high viral titres in the HEK293 
cell line but their separation from helper virus is difficult. Many strategies are currently 
being investigated to combine the advantages of adenoviral vectors with reduced 
immunogenicity and long lasting, high level expression of transgenes typical of other 
viruses, through the creation of chimeric vectors such as adenovirus-AAV or 
adenovirus-retrovirus chimera to achieve viral integration into host DNA coupled with 
efficient infection and high level gene expression. Since adenoviral vectors are very 
efficient gene transfer vehicles mediating transient but high level expression of the 
target gene, these vectors are frequently used in clinical gene therapy studies (Walther 
and Stein, 2000). 
AAV is a single stranded DNA dependovirus belonging to the family of 
Parvoviruses that can infect a broad range of cell types. No pathology has been 
observed with viral infection although the majority of the human population is 
seropositive for AAV. AAV contains 2 genes, rep and cap, encoding polypeptides 
essential for the replication and encapsulation of AAV and flanked by viral ITRs. AAV 
requires an adenovirus or a herpes virus for viral replication and needs stimulation by, 
for example, adenoviral E1 and E4 proteins. In addition, adenoviral E1B and E4 
proteins are required for a productive AAV infection and for the synthesis of the second 
AAV DNA strand. This process is important for the conversion of the single-stranded 
AAV genome into the transcription-competent double-stranded DNA molecule. The 
generation of recombinant AAV (rAAV) particles requires super-infection with an 
adenovirus causing difficulties in obtaining high-quality viral stocks. This is also 
complicated by the difficulty of completely removing helper viruses. Notwithstanding, 
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newer rAAV production systems circumvent these problems by replacing adenovirus 
with adenovirus helper plasmids carrying the adenoviral E2A, E4 and VA genes, which 
are expressed by their endogenous promoters. Co-transfection of rAAV vectors with the 
adenovirus helper plasmid in HEK293 cells generates rAAV particles at high titres. The 
wild-type AAV integrates into a specific region of human chromosome 19 after 
infection, whereas the recombinant virus has lost this site-specific integration, possibly 
by deletion of the rep gene in rAAV vectors (Xiao et al., 1998). For the construction of 
rAAV-based vectors, the rep and cap genes are replaced by exogenous genes and 
internal promoters regulating transgene expression. In contrast to adenoviruses, AAV 
has low immunogenicity, which is important for the use of rAAV vectors in vivo, but 
has only limited capacity for insertion of foreign genes ranging from 4.1 to 4.9kb. 
rAAV vectors are suitable for in vitro and in vivo gene transfer into several organs and 
cells such as muscle, brain, haematopoietic progenitor cells, neurons and liver cells 
(Walther and Stein, 2000).  
HSV-1 is a DNA virus possessing a linear double stranded genome of 150kb 
encoding 70 to 80 genes. This feature determines the large packaging capacity of this 
virus for insertion of foreign genes of 30 to 50kb. The virus has a broad range of target 
cell types, and can infect dividing and non-dividing cells, where it can establish a lytic 
or a latent infection persisting for years. The virus does not integrate into the host 
genome, which is the reason for only transient expression in infected cell populations. 
HSV is of interest because of its large insertional capacity for foreign DNA, its natural 
tropism toward neurons, its relative stability and the ability to obtain high titres of up to 
1012 cfu/ml (Chou et al., 1990). Despite several studies generally demonstrating the 
applicability of HSV vectors for long term expression of transgenes, particularly in 
neurons, there are still numerous safety and technical issues to be addressed such as 
reduction of toxicity after viral infection, possible inactivation of circulating viral 
vectors by host antibodies and risk of recombination (Walther and Stein, 2000). 
 
2.2.6 Viral vector microinjection into the brain 
 
Different physical methods are available for viral vector delivery into the brain: 
stereotaxic injection, intrathecal and intraventricular injection and intravascular infusion 
with or without modification of the blood brain barrier (BBB). The choice of route for 
viral vectors administration affects neuronal cells transduction efficiency and spatial 
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distribution, as well as the extent of transgene expression in the infected cells (Rainov 
and Kramm, 2001). The simplest local approach for viral vectors delivery to a specific 
brain area is the stereotaxic injection: it offers the advantages of low systemic toxicity, 
high local vector concentrations and minimal vector loss to the systemic blood and 
lymph circulation. On the other hand this procedure presents some disadvantages, such 
as limited vector distribution to a few millimetres surrounding the respective injection 
site and the need of multiple injections to achieve wide virus distribution in a large brain 
region. Since the number of injection sites and the single volume of inoculum are 
limited for practical reasons by length of surgery and increasing risk of haemorrhage, 
stereotaxically guided viral vectors injections provide adequate vector delivery to 
spatially limited areas of the brain. Intrathecal virus injection provides minimally 
invasive approach to access to the cerebrospinal fluid (CSF) spaces and a ubiquitous 
distribution of vectors in the CNS but does not permit spatial selectivity of delivery. 
Moreover it requires a large amount of vectors since viruses may be inactivated by CSF. 
Intravascular viral vector applications, in particular intra-arterial injection or infusion, 
are not linked to mechanical injury to brain tissue but provoke major loss of vector to 
peripheral organs, possible systemic toxicity, and need high concentration of vector 
with low rate of neuronal vector delivery. 
In 1994 Nikkhah and colleagues experimentally demonstrated that a minor brain 
damage is provoked by stereotaxic microinjection compared with conventional 
macroinjection with steel needles (Nikkah et al., 1994). In particular they compared the 
effect of injection into striatum with a Hamilton syringe connected to a 0.5mm outer 
diameter (OD) metal cannula or to a glass capillary with an OD of 50-70µm. The results 
showed that glass needle minimized injection trauma and was associated with a more 
extensive functional recovery after surgery. Whittemore and colleagues explored the 
effect of various OD glass tips as well as configuration of the tip (broken, bevelled, fire 
polished) on the deformation of the spinal cord before the tip penetrated the cord 
parenchyma, an indication of the degree of the host tissue damage  (Whittemore et. al., 
2002) (Fig. 5). In addition they investigated the effect of a 1µl Hamilton syringe 
injection since it is widely used in research for injection into the CNS. The results 
showed that injections with Hamilton syringe connected to steel needle caused 
substantial deformation of the spinal cord and a 10% lower cell viability compare to 
glass needle injection, while among the glass needles, bevelled tips performed better 
than broken or polished tips (Table 1).  
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Table 1. Spinal cord deformation provoked by several type of glass micropipetes or 1µl Hamilton syringe 
(Whittemore et al., 2002). 
 
Fig. 5. Example of micropipet tip configurations. (A) beveled, (B) fire-polished, (C) broken, (D) beveled 
with tungsten filament partially lowered (arrow), (E) tip of 1µL Hamilton syringe. The arrowhead 
indicates the center of the opening in the syringe (Whittemore et al., 2002). 
 
They also tested both manual and motorized injection procedures and reported the 
advantages of motorized over manual microinjection to deliver precise small volumes. 
In the motorized procedure the syringes connected to the micropipette is mounted on a 
programmable infusion pump. Some disadvantages are associated at this delivery 
system since it relies on pressure for delivery and the injection volume could be 
influenced by changes in tip and tissues resistances. Moreover small OD diameter 
needles have the potential to become clogged as the tips is lowered in the tissue but this 
problem can be overcame by using a high flow rate while lowering the needle within  
the tissue. 
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2.2.7 RNAi in neurons 
 
Thanks to its feasibility in target gene suppression, RNA interference has been 
used in the last few years to explore the patho-physiology of several diseases. The use 
of RNAi in neuropsychiatric diseases faces the problematic task of targeting gene 
expression in the mammalian brain. Mammalian neurons are non dividing- terminally 
differentiated cells more difficult to transfect in vitro and more sensitive than other 
primary cells to some transfection systems such as lipophilic agents or electroporation. 
Despite this, there are several reports in literature of the ability of siRNA to reduce gene 
expression in mammalian neurons (Numakawa et al., 2004). Moreover, there are 
peculiar characteristics of the brain that can hinder RNAi successful application. Since 
the blood-brain barrier restricts the passive entry of materials from the peripheral 
circulation, systemic administration of siRNAs is almost ineffective to obtain RNAi-
mediated gene suppression in the brain. In addition, a high level of complexity and 
connections in the cellular population are obstacles to achieve the desired gene 
knockdown within a specific set of cells in a particular brain area. Nonetheless in the 
past few years an intense exploration of possible RNAi applications in mammalian 
brain not only in neuroscience but also as a potential therapeutic tool for otherwise 
untreatable neurological diseases was reported (Federici and Boulis, 2007; Hoyer D, 
2007).  
The methodologies for RNAi application in the brain are essentially two: direct 
pre-synthesized siRNAs using several delivery systems or short-hairpin RNA-mediated 
gene knockdown. After their in vitro success in down-regulating gene expression in 
neurons, chemically synthesized siRNAs were tested for their ability to knockdown 
gene expression in the brain. The simplest way to deliver siRNAs is to locally inject 
them in the desired region of the brain. Successful gene knockdown in brainstem and 
hypothalamic nuclei was reported with this method, but only a transient and highly 
restricted injection site suppression was achieved (Makimura et al., 2002). Transfection 
reagents able to efficiently deliver siRNA in the brain have been recently described 
(Hassani et al., 2005). Cationic vehicles, using either polyethylenimine or a mixture of 
lipids and alcohol as well as an aqueous formulation, were tested for their ability to 
deliver siRNA into the cerebral hemispheres of neonatal mice. Only with the aqueous 
formulation of the lipoplex-neutral lipid mixture gene suppression was achieved. Since 
neurons are sensitive to liposomal toxicity, when using a cationic lipid-based 
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transfection reagent it is necessary to investigate the potential metabolic effect on these 
cells (Lingor et al., 2004). Electroporation is able to effectively introduce exogenous 
DNA, RNA or low molecular weight compounds into neurons. This method was 
recently used to regulate the target area of siRNA-induced gene knockdown in the brain. 
Cellular introduction of siRNA was facilitated with local electroporation via electrodes 
implanted 5 mm apart, placed on either side of the siRNA injection site. Following 
electroporation, siRNA-mediated down-regulation of target mRNA was found to be 
transient, with maximal knockdown of 80% obtained after 6 days, returning to basal 
levels in a 2- to 4-week period. The target region did not show any signs of cytotoxicity 
occasionally found with this method (Akaneya et al., 2005). Indeed electroporation may 
be a powerful technique for investigating regionally defined neuronal circuits involved 
in disease pathology in animals.  
The previously discussed methods, in conjunctions with the use of short-hairpin 
RNA, can be used for phenotyping of genes expressed in specific brain regions. These 
approaches are not ideal for the suppression of broadly expressed genes and for genes in 
which their mRNA processing events or the brain regions relevant to their physiological 
actions are lacking. To address this, prolonged siRNA administration, using osmotic 
mini-pumps was used to efficiently produce gene silencing throughout the whole brain 
(Davies, 2005) without neurotoxic effects possible associated with the use of 
transfection and electroporation.  
 
Fig. 6. siRNA infusion, using osmotic minipumps, for widespread knockdown of gene expression in the 
brain. (A) Cross-sectional view of an osmotic minipump (http://www.alzet.com). (B) The osmotic 
minipump is subcutaneously placed on either side of the mouse, with its flow moderator connected to a 
catheter that is attached to a brain infusion cannula on the other end. The brain infusion cannula is 
stereotaxically placed so as to infuse the siRNA into the brain. Subsequently, siRNA is directed via the 
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catheter to the brain infusion cannula and infused into the dorsal third ventricle. (C) A schematic is 
shown, illustrating the extent of gene knockdown obtained upon infusing siRNA for 2 weeks into the 
dorsal third ventricle. The intensity of yellow color roughly denotes the magnitude of knockdown attained 
in various brain regions for a number of genes (Thakker et al., 2006). 
 
An osmotic minipump contains a high-osmolality chamber that surrounds a 
flexible and impermeable, reservoir filled with the siRNA containing vehicle (Fig. 6). 
Subsequent to the subcutaneous implantation of this minipump, extracellular fluid 
enters through an outer semi-permeable membrane into the high-osmolality chamber, 
thereby compressing the reservoir to release siRNA at a controlled, pre-determined rate. 
siRNA, released from the pump, is directed via a catheter to a stereotaxically placed 
cannula for infusion into the brain. There are several examples in the literature of 
successful and widespread gene suppression in the brain achieved with the minipump 
method such as the knockdown of P2X3, which is implicated in pain, in the rat dorsal 
root ganglia after chemically modified siRNA intratechal infusion (Dorn et al., 2004). 
No signs of neurotoxicity, with respect to neuroanatomical damage, spinal 
inflammation, or hind-limb paralysis, were noted after intrathecal siRNA infusion even 
if at rates very high (0.4 mg/day for up to 6 days). Similar results were achieved by 
Thakker and colleagues, who demonstrated that intracerebroventricular (i.c.v.) infusion 
of siRNA, using osmotic minipumps, lead to a specific knockdown of gene expression 
in the brain (Thakker et al., 2004, 2005). They obtained a significant reduction of 
mRNA for the dopamine transporter (DAT) of 33% in the substantia nigra compacta 
and ventral tegmental area, following infusion of an unmodified siRNA into the dorsal 
third ventricle over 2-weeks. Down-regulation of the DAT protein was also 
demonstrated. Concomitant to the siRNA-induced knockdown of DAT, a time-
dependent hyperlocomotor phenotype developed in the mice, similar to that obtained 
after infusing a pharmacologically selective DAT inhibitor. More recently, suppression 
of the serotonin transporter (SERT) gene, implicated in the etiology of anxiety and 
depression, was achieved after a 2-week siRNA infusion into the dorsal third ventricle. 
This decrease in mRNA levels was reflected in a widespread and specific reduction in 
the levels of the SERT protein in the brain and in an antidepressant-like behaviour in the 
mouse forced swim test, an effect identical to that obtained from mice receiving a 
pharmacologically selective SERT inhibitor. siRNA infusion into the dorsal third 
ventricle using osmotic minipumps is an effective means for producing specific and 
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bilateral knockdown of gene expression in the brain, evading the need for repeated 
siRNA injections and permitting the prolonged siRNA infusion over time by replacing 
the empty minipump with newly filled pumps. However, a disadvantage in the use of 
this system is the cost associated with the synthesis of siRNA, depending on the 
concentration and infusion period required in order to achieve a stable and significant 
gene knockdown and the technical difficulties in the use of minipumps.  
As previously seen, one of the major disadvantages of using pre-synthesized 
siRNA in vivo is the transient nature of gene knockdown. Consequently, DNA vectors 
have been developed to constitutively express shRNAs in order to achieve a long-
lasting siRNA production intracellularly. These DNA vectors incorporate either the 
RNase P H1 (H1) or the U6 small nuclear RNA (U6) polymerase (Pol) III promoters to 
express shRNAs with well-defined 5’ and 3’ ends. At the moment, only one study has 
reported the suppression of target gene expression after liposomal transfection of an H1 
promoter-driven shRNA expression vector, but this suppression was transient 
(Makimura et al., 2002). It is unclear if liposomes would further enhance the duration of 
RNAi-mediated gene silencing and subsequent phenotyping, without eliciting cytotoxic 
or off-target effects. More successful was the application of electroporation to deliver 
shRNA-vectors (see Konishi et al., 2004). In any case the most investigated technique 
to deliver and express shRNA in the brain is through recombinant viral vector. Among 
the retroviral vectors, lentiviral vectors have been used to deliver shRNA in the brain 
thanks to their ability to infect actively dividing as well as non-dividing, post-mitotic 
cells such as neurons and achieve extended expression of shRNA. However, the fact 
that retroviruses integrate their genetic material into the host genome also enhances the 
risk of insertional mutagenesis. In the first proof-of-concept study, an HIV-1-derived 
lentiviral vector expressing a enhanced green fluorescent protein (eGFP) targeting 
shRNA under the control of a U6 promoter was injected into the striatum of adult mice 
(Van den Haute et al., 2003). One week after injection, eGFP expression from a co-
injected eGFP-encoding lentiviral vector was completely silenced. HIV-1-based 
lentiviral vectors have been used also for extended knockdown of endogenous gene 
expression in motor neurons of the brainstem and spinal cord. In mice expressing a 
mutated form of the human Cu/Zn superoxide dismutase (SOD1) (SOD1G93A), 
increase in the survival and function of motor neurons and a marked reduction in the 
muscular atrophy was observed after SOD1-shRNA expression driven by HIV-1-based 
lentiviral vector (Gurney et al., 1994).  
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Adenoviruses, which do not integrate into the host genome, exhibit comparable 
transduction efficiencies in neuronal cells to lentiviruses. A substantial knockdown of 
eGFP expression has been demonstrated in the striatum of adult eGFP-expressing mice 
5 days following local injections of recombinant adenoviral shRNA constructs (Xia et 
al., 2002). However, the in vivo use of adenoviruses has been limited by the possible 
activation of immune response.  
In contrast, recombinant adeno-associated viruses are weakly immunogenic and 
are episomal, not integrating into the host genome. They also transduce both dividing 
and non-dividing, post-mitotic cells such as neurons. Thanks to this property, they 
present an attractive alternative for the delivery of shRNAs into the brain, particularly 
the AAV serotype 2 (AAV2). Infection of specific neurons in the brain has been 
achieved with pseudotyping, using capsid proteins from AAV1 along with those of 
AAV2 for cross-packing the shRNA-expressing vector containing AAV2 inverted 
terminal repeats (Cao et al., 2004) to create recombinant AAV1/2 chimeric vectors. 
These vectors have been demonstrated to efficiently deliver an shRNA to hippocampal 
neurons of young rats (Cao et al., 2004). AAV expressing vascular endothelial growth 
factor (VEGF) shRNA specifically suppress mRNA by 50% as well as protein by 15%. 
Tropism for midbrain dopaminergic neurons was also revealed after injecting AAV-
shRNA vectors targeting the mRNA of tyrosine hydroxylase (TH), a rate-limiting 
enzyme in the biosynthesis of catecholamines, into the substantia nigra compacta or 
ventral tegmental area of adult mice (Hommel et al., 2003). shRNA-mediated 
downregulation of TH was persistent for a period of up to 50 days post-transduction and 
rostrocaudally spread across the substantia nigra compacta. In addition reduction in 
protein levels and decrease in a motor-deficit was demonstrated. Recombinant AAV-
shRNA vectors were also used to treat polyglutamine disorders, such as Huntington’s 
disease (HD; Harper et al., 2005) and spinocerebellar ataxia type 1 (SCA1; Xia et al., 
2004). The mutant huntingtin was targeted by AAV-shRNA vectors in the striata or 
cerebellar lobules of a murine model of HD, achieving successful target gene and 
protein suppression and a significant reduction in the HD neuropathology. Similarly, 
recombinant AAV vectors expressing a human ataxin-1-targeting shRNA from the H1 
promoter (Xia et al., 2004) were injected at multiple sites in the midline cerebellar 
lobules of SCA1 mice, expressing the human ataxin-1 disease allele in cerebellar 
Purkinje cells. Also in this study, successful target suppression was achieved, associated 
with a reduction in the typical phenotypic characteristic of this pathology. These results 
 48
confirm the ability of AAV-shRNA vectors to mediate sustained and prolonged 
suppression of target gene in specific brain area. 
A non-viral transvascular delivery of shRNA-expressing DNA vectors was 
explored by Pardridge and colleagues (Zhang et al., 2003) to suppress genes broadly 
expressed in the brain. Their approach consists of intravenous (i.v.) injections of vector-
encapsulating liposomes (PILs) that are externally conjugated to PEG to restrict the 
uptake to the reticuloendothelium and extend their half-life in the bloodstream. In 
addition, PEG also binds to receptor-specific peptidomimetic monoclonal antibodies 
that facilitate organ- or tissue-specific delivery. Antibodies directed against the insulin 
or transferrin receptors enable a receptor-mediated transcytosis of PILs across the BBB 
and endocytosis into the brain cells. PIL-mediated RNAi delivery into brain was tested 
by targeting human epidermal growth factor receptor (EGFR), in brain tumors of adult 
rats (Zhang et al., 2004). Consequent to the weekly i.v. injections of PILs, a marked 
decline in the target protein levels was noted in cancer cells, correlated with an 
approximate doubling in the survival time of shRNA-expressing mice. Despite that, the 
impossibility to restrict gene knockdown to specific cell populations within the brain 
and the limited longevity of the PIL-mediated RNAi response restricted the use of this 
approach. 
An alternative method to investigate neuronal gene function in vivo is represented 
by the development of constitutive and inducible transgenic RNAi animals. In fact using 
accurate inducible Cre expression strategies for transgenic siRNA expression, it is 
possible to study neuronal genes (Ventura et al., 2004). 
To choose the appropriate RNAi approach for evaluating neuronal gene function 
in vivo, it is important to consider the proprieties of the target gene itself such as the 
stability and/or turnover rate of the encoded mRNA, and protein. Genes with short 
mRNA and/or protein half-lives (hours to days) can be effectively silenced using 
transiently effective approaches, such as local injections or transfection of si/shRNA. In 
contrast, genes with longer half-lives (days to weeks) require an extended knockdown, 
that can be achieved either by repeated electroporation of siRNA, by injecting PIL 
encapsulating shRNA-expressing vectors, by minipump infusion of siRNA or by 
injection of recombinant viral shRNA-vectors. Stable knockdown of gene expression 
can be obtained using transgenic RNAi mice. Another consideration that needs to be 
taken into account is the local or widespread application of the siRNA required. RNAi 
offers an immense potential in not only investigating the patho-physiological role for 
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genes that are expressed in the brain, but also for generating the relevant animal models 
of neurological and psychiatric disorders. RNAi holds promise for the development of 
novel therapeutic strategies to treat neuron-based disorders that are at present yet 
difficult to treat, such as neuropathic pain and depression (Dorn et al., 2004; Thakker et 
al., 2005), as well as dominantly inherited neurological diseases that result from gene 
mutations like HD, even if more studies are needed to explore the effective benefit of 
the RNAi therapeutics. 
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3. MATERIALS AND METHODS 
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3.1 IN VITRO WORK 
 
3.1.1. Cell cultures 
 
The rat pheochromocytoma PC12 cell line and a sub-clone thereof, PC12NS1 
were grown in F-12 and F-10 respectively medium with 15% horse serum, 2.5% fetal 
bovine serum, 2mM Glutamine, penicillin and streptomycin (both 100U/ml). Human 
HEK293A cells were grown in D-MEM with 10% fetal bovine serum (Sigma, UK), 
2mM Glutamine, penicillin and streptomycin (both 100U/ml) and rat P2X4 and P2X7-
HEK recombinant cells were grown in the same medium with G418 geneticin 0.3mg/ml 
for selection. All the cells were grown at 37 °C in a humidified atmosphere of 95% air 
and 5% CO2. All reagents were provided from Gibco, UK. 
 
3.1.2 Primary cells 
 
Rat astrocytes were by Steve Skaper (GlaxoSmithKline, Harlow) and have been 
growth in D-MEM with 10% fetal bovine serum, 2mM Glutamine, penicillin and 
streptomycin (both 100U/ml) at 37 °C in a humidified atmosphere of 95% air and 5% 
CO2. 
Primary cultures of hippocampal neurons were prepared as described in previous 
works (Skaper SD et. al., 1990) from rat hippocampi isolated from E17-19 embryos. 
Time-mated pregnant rats (Wistar-Han by Charles River, UK) were killed by CO2 
asphyxiation, fetuses were removed by caesarean section and fetal hippocampi were 
dissected from surrounding brain tissue. After the meningi removal, hippocampi were 
isolated, enzymatically dissociated and purified with the papain dissociation kit 
(Worthington, UK). Neurons were plated at 1.5x105 cells/well in neurobasal medium 
(NBM) containing B27 supplement with anti-oxidants, 0.5 mM L-glutamine, 100/U 
penicillin/streptomycin and 1mM sodium pyruvate (Sigma, other reagents from Gibco) 
in plates pretreated with poly-D-lysine 50µg/ml (Sigma). Cultures were lysate 7 days 
later and submitted for TaqMan analysis or western blot. This work complied with 
national legislation for animal handling and with the GSK policy on the Care of Use of 
Animals and related codes of practice. 
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3.1.3 siRNA design and transfection 
  
siRNA sequences were designed and then synthetized using commercial 
algorithms (in this case Ambion) based on Tuschl design rules (target sites beginning 
with AA, 3' UU overhangs for both the sense and antisense siRNA strands, ≈50% G/C 
content) and considering an high number of physical characteristics able to influence 
siRNA potency and specificity, including Tm, nucleotide content of the 3' overhangs, 
siRNA length and nucleotide distribution over the length of the siRNA. Moreover, a key 
step in the algorithm is a stringent analysis of each siRNA sequence to maximize target 
specificity (see Fig. 7 for an example of a siRNA sequence). 
For the siRNA delivery into the cells, Gemini GSK250910, a GSK propriety 
surfactant able to form a complex with DNA and RNA and deliver them inside the cell 
was used, at final concentration of 3.5µg/ml while siRNA final concentration was 
100nM. A modified version of the reverse transfection protocol was performed: each 
siRNA was mixed with the GSK surfactant at the appropriate concentration in general 
medium, left for 15min at room temperature and then the cell suspension was mixed 
with the siRNA/GSK surfactant complex and seeded at 6.3x105 cells/ml. After 24hr, the 
medium was replaced with a second dose of siRNA/GSK surfactant complex. After 
48hr cells were harvested for TaqMan analysis (adding 100µl/well of Lyses Buffer + β-
Mercaptoethanol). 
 
P2X7 (NM_019256): 
1 GGUGACAGAGAAUGUCACGtt 
2  GGCCAAGAACAGAAGCUGUtt 
3 GGAAAAUGGCAUGGAAAAGtt 
 
Fig. 7. Ambion P2X7 siRNA sequences. 
 
3.1.4 shRNA design, cloning and transfection  
 
shRNAs were designed based upon siRNA sequences, except these containing 
streches of three or more uridine or adenosine, since these sequences could be inhibitory 
of shRNA expression by increasing the chance of premature termination. A guanine at 
the 5’ end of the siRNA sequence (to increase the transcription efficacy) and the 
Brummelkamp loop at the 3’ were inserted, then the complementary and inverted 
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sequence to form the stem and at the end of the template the termination site (TTTTT). 
From this sense strand the complementary strand (or antisense strand) was designed and 
in this way 4 shRNAs were constructed for each gene. The Brummelkamp loop was 
chosen because it is one of the most frequently reported loop sequence (Fig. 8). The two 
complementary oligos were annealed to form the shRNA (a double strand DNA) which 
was then cloned into a linearized plasmid vector (pENTR∆U6) carrying the human U6 
promoter. This promoter has been used because it normally drives the expression of 
short non coding RNAs with high efficiency. Prior to cloning the shRNA, the vector 
was linearized with the 2 enzymes EcoRI and BbsI producing four nucleotides 
overhangs at each 5’ end (encoding the last four nucleotides of the U6 promoter and 
first four nucleotides of RNApolIII terminator site), to direct the directional cloning of 
the oligo downstream the U6 promoter. The transfected clones, selected for the 
antibiotic resistance, were sequenced to identify the vectors carrying the correct shRNA, 
and then isolated to prepare a large amount of vectors. Three shRNA carrying vectors 
for P2X2 and P2X4 and all the initial four shRNA vectors for P2X7 were obtained. 
These U6-shRNA plasmids were transfected in different cell types using the GSK30064 
Gemini 8-10µg/ml or the commercial Lipofectamine 2K 1.5ng/μl (Invitrogen, UK). For 
plasmid transfection of astrocytes, the AMAXA nucleofection system (Amaxa GmbH, 
Germany) was used: this technique uses a unique combination of electrical parameters 
and cell-type specific solutions and provides the ability to transfect even non-dividing 
cells. Different amounts of plasmid DNA were tested (2-5 μg), achieving roughly 80% 
DNA delivery and good cell viability measured transfecting astrocytes with a GFP 
expressing vector. Three days after plasmid transfection the cells were harvested for 
TaqMan analysis or western blot. 
 
P2X4-1 
                       5’-ACCGTCAGCTCGGTGACAACCAATTCAAGAGATTGGTTGTCACCGAGCTGATTTTTG-3’ 
      3’-AGTCGAGCCACTGTTGGTTAAGTTCTCTAACCAACAGTGGCTCGACTAAAAACTTAA-5’ 
 
Fig. 8. Example of a shRNA sequence. 
 
3.1.5 AAV and Ad vector production 
 
For the AAV viruses production, the U6-shRNA cassettes were inserted in a 
AAV2-based shuttle plasmid, the pZAC2.1eGFP3 vector, carrying part of the wild type 
 54
viral sequence (Fig. 9). This vector was then packaged into AAV6 capsids by the Viral 
Vector Core, University of Pennsylvania for generation of high titer of viral vectors 
stock. The U6-shRNA cassettes were amplified by PCR from the pENTR-U6shRNA 
vectors, cut with the XbaI enzyme and purified from the gel band. The DNA fragment 
obtained presents the 3’-end overhang compatible with the shuttle pZAC vector cut with 
the NheI enzyme and dephosphorilated at the 5’-end to prevent its closing. After the 
ligation reaction and E.Coli transformation, the clones carrying the pZAC vectors with 
the correct shRNA cassette were isolated and the vectors produced in large amount. To 
produce the final viral particles, the recombinant AAV vectors were co-transfected with 
the adenovirus helper plasmid in 293 packaging cells. Finally the viruses were purified 
and resuspended in sucrose and the final titer for each viral vector was determined by 
PCR. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9. Map of AAV2-shRNA shuttle plasmid.  
 
For the AdV5 vectors production, the U6-shRNA cassettes were cloned in the Ad5 
shuttle plasmid through a recombinant reaction (using the Invitrogen clonase enzyme 
mix) and the vectors carrying the right shRNA sequences were selected for antibiotic 
resistance and prepared in large amount. The Ad5 shuttle vector contains a part of the 
human Ad5 wild type sequence, including left and right inverted terminal repeats (ITR), 
 
Legend: 
ITR:    Inverted terminal repeated 
PU6 -  shRNA - Pol III ter:  Human U6 promoter + shRNA sequence + Polymerase III terminator 
CMV promoter:   Cytomegalovirus promoter 
SV40 intron:   Simian vacuolating virus 40 intron 
eGFP:    enhanced Green Fluorescent Protein 
WPRE:    Woodchuck Hepatitis Post-transcriptional Regulatory Element 
bGH polyA:   Bovine Growth Hormon polyadenylation site 
ORI:    origin 
AmpR:    Ampicillin resistance site 
 
ITR pZAC2.1eGFP3-shRNA
                                                       
        PU6 -  shRNA - Pol III ter    CMV promoter   SV40 intron      eGFP     WPRE  bGH poliA   
ITR 
AmpRORI 
PacI PacI 
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late genes and packaging signal while the E1 region necessary for the replication, and 
the E3 region are deleted (Fig. 10). The vector was digested with the PacI enzyme to 
excise the viral genome sequence from the plasmid and allow proper viral replication 
and packaging when transfected into HEK293A cells (using Lipofectamine 2K as 
delivery agent). These cells exhibit a flattened morphology, enabling easier 
visualization of viral plaques (CPE, cytopathic effect) that typically are observed 7-10 
days post-transfection. When these are visible, the cells and media are harvested and the 
viral particles inside the cells released, through several freeze/thaw cycles. These are 
used to infect a higher number of cells to obtain a large amount of viral vectors. The 
viral vectors were then purified using the CsCl gradient and the viral titer determined 
through visualization of the viral hexon proteins (using the Adeno-X Titer kit by BD 
Biosciences, UK). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 10. Map of Ad5 shuttle plasmid.  
 
3.1.6 Cell infection 
 
Rat astrocytes were seeded at 2x105 cells/ml in 24 or 96 well plates, for western 
blot or TaqMan analysis, respectively. The following day, the cells were infected with a 
specific amount of virus, simply by adding the virus to the well and diluting it in 2% 
pAd-hU6-shRNA
                                                       
           5’ITR                       attB1 – PolIII term -  shRNA – PU6 – attB2    
         3’ ITR          wtAd5 (E3 and  E1)              
Legend: 
ITR:   inverted terminal repeated (5’ ITR contains packaging signal) 
PU6 -  shRNA - Pol III ter: Human U6 promoter + shRNA sequence + Polymerase III terminator 
attB:   site for recombination (Invitrogen Gateway system)   
wtAd5 (E3 and E1):  human Ad5 sequences (E3 region deleted) 
AmpR:   Ampicillin resistance gene            
pUC ori:   origin   
pUC ori 
AmpR 
PacI 
PacI
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fetal bovine serum medium if necessary. The medium was not replaced (for longer 
incubations, fresh medium was added.) At the time point chosen the cells were lysed to 
extract protein or RNA. 
Rat hippocampal neurons were supplied in 24 well plates, since the level of P2XR 
expression in embryonic hippocampal cultures is quite low. The neurons were infected 
with the virus diluted in 250µl of NBM. The day after additional 250µl of fresh medium 
were added to each well and an equal volume was added 3 days after infection. At the 
time point chosen the cell plates were lysed for TaqMan or western blot. 
 
3.1.7 TaqMan analysis 
 
TaqMan primers and probes were designed using the software Primer Express; 
RNA extraction has been performed using the Promega SV96 kit and the reverse 
transcription to synthetize cDNA with Applied Biosystem cDNA synthetize kit.  
TaqMan analysis was performed using the Applied Biosystem method, using the 
TaqMan® Universal PCR Master Mix in the 384 well format with the ABI PRISM 
7900 sequence detector. For each analysis, the GAPDH normalized copy numbers of 
P2X2, P2X4 and P2X7 mRNA was measured. 
 
3.1.8 Western blot for P2X receptors detection 
 
The whole cell lysate was obtained by harvesting the cell pellet in SDS + 2.5% β-
Mercaptoethanol; hippocampal neurons were lysed with LDS buffer + reducing agent 
and the protein samples were run on Nupage 4-12% Tris Bis gel with MOPS SDS 
buffer (all Invitrogen, UK). To obtain the membrane fraction the cell pellet was 
resuspended in membrane buffer (10mM Tris-HCl, 0.1M EDTA pH 7.5 and protease 
inhibitors cocktail from Boerhinger, Germany), sonicated to homogenize cell 
suspension and passed through a 25 gauge needle. The nuclei pellet was isolated by 
centrifugation at 1200xg for 10min at 4°C and resuspended in RIPA buffer and protease 
inhibitors (0.01M Tris pH 7.2, 0.15M NaCl, 1% Triton X-100, 0.1% SDS, 1% sodium 
deoxycholate, 0.02% sodium azide and 5mM EDTA) and the supernatant was 
centrifuged for 20min at 13000rpm to yield the membrane fraction (resuspended in 
RIPA buffer) (MLA-80, Benchtop Ultracentrifuge). To obtain a crude membrane 
fraction from whole rat brain, the tissue was dissected with a scalpel, washed in 
membrane buffer and protease inhibitors, spun briefly to pellet, then resuspended in 
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membrane buffer and homogenised in a glass potter homogeniser (three cycles of 20 
strokes, spinned pellet, re-suspended and re-homogenised). At the end, the homogenised 
supernatant was centrifuged at 18000rpm for 30min (MLA-80, Benchtop 
Ultracentrifuge), the pellet washed in 20mM HEPES and re-centrifuged at same speed. 
The crude membrane pellet was resuspended in RIPA buffer on ice for 1hr and then 
stored at -80°C. 
The protein amount in each sample was quantified using the Coomassie plus 
Bradford Assay kit (Pierce, UK), following the manufacturer’s instructions. 
Both whole cells lysate and membrane cell fractions were heated 2 minutes at 
85°C prior to loading; a maximum of 25µl of sample was subjected to electrophoresis 
on Novex 4–12% Tris-Glycine Gel and transblotted onto a nitro-cellulose membrane. 
Prestained protein standard was used to visualize successful transfer and to measure 
molecular weight of the subsequent signal (MagicMark™ Western Protein Standard, all 
Invitrogen, UK). The membrane was blocked with PBS containing 0.1% Tween (PBST) 
and 5% skimmed milk (Marvel, UK) for 2 hours, and then washed three times at 10 min 
intervals with PBST. Washed membrane was incubated with the appropriate diluition of 
the primary antibodies in PBST + 5% skimmed milk overnight at 4°C, then washed 3 x 
10 minutes in PBS/Tween and incubated with the peroxidase-conjugated secondary 
antibody (DakoCytomation) at 1:5000 diluition in PBS/Tween/Milk for 2 hours at room 
temperature (RT). The membrane was then washed 5 x 10 minutes in PBS/Tween and 
the proteins visualized after addition of the substrate using the Pierce West-Dura kit 
(Pierce, UK). The P2X antibodies used were: for P2X2 Alomone Labs APR-003, Santa 
Cruz (V-17) sc-12211 and the Santa Cruz (S-16): sc-12212; for P2X4 Chemicon 
AB5226, Santa Cruz (C-15): sc-15190, Santa Cruz (N-15): sc-15187 and for P2X7 
Chemicon AB5246, Santa Cruz (L-20): sc-15200, Santa Cruz (H-265): sc-25698. Each 
membrane was also blotted for the α-tubulin (Sigma, UK), to assess the amount of 
protein in each sample.  
Western blot bands were quantified with the GeneSnap program, normalizing with 
α-tubulin staining. 
 
3.1.9 Immunocytochemistry (ICC) analysis 
 
For this analysis astrocytes were seeded on a 12 well plate, while hippocampal 
neurons were supplied in a 12 well plate on coverslips. Both culture types were plated at 
the same concentration (2x105 cell/ml). Cells were fixed in 4% paraformaldehyde (PFA) 
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for 15 minutes under a chemical hood, and then washed 3 x in 100µl PBS. After 
fixation, the cells were permeabilized with 100µl 0.1% Triton (TTX-100) in PBS for 10 
minutes at RT. Non-specific binding was blocked by incubating cells with 100µl 1% 
bovine serum albumin (BSA) in PBS for 1 hour at RT. The primary anti-P2X antibodies 
(also used for western blot analysis) were diluted 1:200 in 1% BSA/PBS, applied to the 
plates and incubated for 1 hour at RT, followed by 3 washes with 100μl 1% BSA/PBS. 
50μl of the secondary antibody (anti-rabbit Alexa-488) diluted 1:200 in 1% BSA/PBS 
was incubated with cells for 1 hour at RT. Plates were then washed 3 times with 100µl 
PBS, re-permeabilized for 10 minutes, then incubated with the astrocytic or neuronal 
marker antibody 1:3000 (GFAP Sigma G3893 and ß3-tubulin Abcam 7751, 
respectively). After 3 washes, cells were incubated with the secondary anti-mouse 
antibody Alexa-594 diluted 1:400 (Alexa, Invitrogen, UK). Results were then visualized 
with fluorescence microscope.  
 
3.1.10 IL-1β release ELISA  
 
For this assay microglial cells in a 96 well plates (2x104 cells/well) were infected 
with different amounts of Ad5 virus and treated 48 hours later with 1µg/ml LPS 
(Invitrogen, UK). After 24 hours, medium was removed, cells were washed with 
HBSS/1mM CaCl2. 1mM of the P2X7 antagonist, PPADS (Sigma, UK), in HBSS/CaCl2 
was added at some wells and incubated for 15 minutes at 37°C. 300µM of the P2X7 
agonist, BzATP (Sigma, UK), in HBSS/CaCl2 was then added and incubated for 30 
mins at 37°C. The medium was transferred to a new 96 well plate and stored at -80°C. 
The ELISA was performed using the Quantikine Rat IL-1ß kit RLB00 (R&D Systems, 
UK) following the manufacturer’s instructions. 
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3.2 IN VIVO EXPERIMENTS 
 
3.2.1 Glass needle preparation 
 
For virus injection into specific area of the brain, bevelled micropipette tips were 
prepared with 30-40µm OD: borosilicate capillary tubes were chosen since this material 
is a neutral charge glass used for chemistry applications. In particular, thin-walled with 
internal filament borosilicate needles (Hilgenberg GmbH, 0.15mm filament diameter, 
1.5mm OD and 0.315mm wall thickness) were produced using a puller for 
electrophysiology (Hans Ochotzki). The internal filament helps to produce an efficient 
surface tension of the liquid, avoiding dispersion and glass-adhesion of the viral vectors.  
Glass needles were prepared shortly before the surgery with the following 
parameters: position of carriage 7 and 16 and temperature t1=3.0 e t2=8.5. The OD of 
the needles produced with these parameters is roughly 20-40µm at the tip and 
approximately 100-200µm 8mm distal from the tip. Maximum needle penetration in the 
tissue is 6mm. A certain variation in the diameter is expected, since this instrument is 
highly sensitive to environmental conditions changes, such as temperature, humidity, 
dust, etc. 
 
3.2.2 Animal handling 
 
Male Wistar Han rats weighing 240-260 grams were used (Charles River, Italy). 
Animals were housed in a temperature- (20-22°C), light- (12 h light/dark cycle) and 
humidity- (55-65%) controlled environment, with ad libitum commercial rodent pellets 
and water provided. After surgery the animal were individually housed. Locomotor 
activity and basal health conditions were monitored twice a day for each animal. After 
completely recovering animals were housed in groups proportional to the size of the 
cage. This work complied with national legislation for animal handling. 
 
3.2.3 Surgery 
 
Anesthesia was induced with a mix of 87 mg/kg  ketamine and 13 mg/kg xylazine 
injected intraperitoneally (i.p.) and then maintained with isoflurane. Animals were 
mounted into a stereotaxic device (Narishige, Japan) with an incisor bar set at -5mm. A 
midline incision was made and two small holes were drilled in the skull in 
correspondence with the dorsal and ventral hippocampal dentate gyri (DG). The 
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coordinates were calculated from bregma according to “A Stereotaxic Atlas of the Rat 
Brain” [Pellegrino et al., (2nd edition), 1979].  
Dorsal  DG coordinates (tav. 39): 
- Anterior-Posterior: -1.7mm  
- Medio-Lateral: -1.2mm  
- Dorso-Ventral: +3.9mm; 
- ventral DG (tav. 49): 
- Anterior-Posterior: -3.4mm  
- Medio-Lateral: -4.7mm  
- Dorso-Ventral: +6.5mm. 
 
The borosilicate needle, pre-treated with ether and washed with 70% ethanol, was 
mounted in a pipette holder (WPI, USA) connected to a 50µl Hamilton microsyringe 
with clear PTFE tubing (Fig. 11).  
The Hamilton microsyringe was mounted on a programmable infusion pump and, 
to avoid damage of the neuronal area, a low controlled rate of liquid infusion was 
chosen. The injection system was washed with ethanol, sterile water and then filled with 
sterile physiological solution.  
Each viral vector was diluted to the final viral titer of choice with sterile PBS and 
0.01% Trypan blue (Sigma). Approximately 8µl of viral solution were drawn up and a 
bubble of air was used to separate the viral solution from the saline solution. The tip 
was then lowered into the dorsal or ventral hippocampus and the selected volume of 
viral vector was injected using the infusion pump at the desired flow rate. The injector 
remained in place for an additional 1 minute following infusion. Animals were housed 
in a warm cage until recovery from surgery. 
 
Fig. 11. In house injection system with glass micropipette used for viral vectors injection. 
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3.2.4 Trypan blue visualization 
 
To check the infusion coordinates, rats infused with a Trypan blue solution 
(0.05% in physiological solution, Sigma, Italy) were sacrificed through decapitation. 
The brain was quickly removed and slowly frozen in isopentane at -80ºC and conserved 
at -80ºC for 3-4 hours. The brain was then mounted with OCT Embedding matrix 
(Vetrotecnica, Italy) and placed into a cryostat (Leika, UK) at -18ºC for 1 hour. 20µm 
section were cut and attached to polarized glass slides (Super Frost Plus, Vetrotecnica, 
Italy); then quickly immersed in 1g/l Hematoxylin solution (Sigma) to stain the nuclei 
and immediately visualized under phase contrast microscope. A qualitative evaluation 
of anatomical damage, using commonly accepted anatomical criteria for the structure of 
the adult rat hippocampus, was carried out on hematoxylin stained slices.  
 
3.2.5 TaqMan analysis 
 
Animals were deeply anesthetized with ether and decapitated. The brain was 
quickly removed under RNAse-free conditions and the hippocampus from each cerebral 
hemisphere was collected and placed in a Eppendorf tube containing microbeads 
(QBiogene, Italy) in 800µl RNA-Later solution (Qiagen, Italy) and incubated at 4ºC for 
24 hours. The RNA-Later solution was removed and the samples were frozen in cold 
isopentane and stored at -80ºC until processed. The tissue was homogenized with a 
Ribolyzer (Hybaid, Italy) at speed 6 for 20 seconds followed by 1 minute incubation on 
ice. This procedure was repeated twice. The samples were then centrifuged at 5000xg 
for 10 minutes at 4ºC. The RNA was extracted using the RNeasy midi kit, following the 
manufacturer’s instructions with an additional DNase I treatment to remove any 
genomic DNA carryover (all Qiagen, Italy). Purified total RNA was eluted in RNase-
free water and stored at -80°C. Quality control evaluation of RNA samples was 
performed by spectrophotometric analysis (260nm/280nm ratio ≥1.9) (Ultrospec 1000, 
Pharmacia Biotech) and visual inspection of rRNA integrity (28s and 18s) with the 
Agilent 2100 Bioanalyzer (Agilent Technologies). Total RNA (500ng) was converted 
into single stranded cDNA with the Invitrogen Super Script II RNase H Reverse 
Transcriptase (RT) following the manufacturer’s instructions (all Invitrogen Italy). For 
each sample 2 RT+ and 1 RT- reactions were performed respectively, with or without 
the enzyme as internal controls. The final product was directly used for TaqMan 
analysis. The analysis was performed with the Applied Biosystem method (Applied 
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Biosystem, Italy), using the TaqMan® Universal PCR Master Mix in a 96 well format 
with the ABI PRISM 7900 sequence detector. Each sample was run in duplicate and the 
copy number was evaluated using a standard curve of a serially diluted solution of rat 
genomic DNA (Clontech). GAPDH copy number for each sample was used to 
normalize P2X2 and P2X7 mRNA levels.  
For Ad5 genome quantisation, the DNA was isolated from the injected samples 
using a Qiagen DNA/RNA midi kit allowing parallel extraction of DNA and total RNA 
following the manufacturer’s instructions (Qiagen, Italy). DNA was eluted in water and 
stored at -20ºC. The concentration was determined by spectrophotometric analysis 
(Ultrospec 1000, Pharmacia Biotech). Quantification was performed by TaqMan 
analysis with 250ng DNA in each well, using rat genomic DNA as a negative control 
and calculating the copy number using several dilutions of the plasmid pAd5-
destination vector-hU6-P2X7-4. 
 
3.2.6 Histology and immunohistochemistry 
 
Animals were deeply anesthetized with a mixture of 87mg/kg ketamine and 
13mg/kg xylazine prior to intracardial perfusion with 200ml of physiological solution 
followed by 100ml/100gr of 4% PFA in PBS. Brains were removed and placed in 4% 
PFA for 1 hour at 4ºC, followed by 20% sucrose in 4% PFA for 48 hours at 4ºC for 
cryoprotection. The brain was then slowly frozen in isopentane at -80ºC and conserved 
at -80ºC (all reagents form Sigma). For animals injected with GFP expressing virus, 
sections were collected anteriorly and posteriorly to the injection site to determine the 
anatomical boundaries of hippocampal GFP expression. 30µm-thick sections, obtained 
with a cryostat (Leika, UK), were soaked in PBS, positioned on a polarized glass slide, 
left overnight (ON) to dry at RT and then stored at 4ºC. GFP expression was visualized 
with the Leica DMRA2 fluorescence microscope (Leica, Italy) and slices were then 
processed for GFP and GFAP or Microtubule Associated Protein 2 (MAP2) staining. 
The slides were washed in PBS 10 minutes at RT and then washed in 0.3% Triton in 
PBS for a further 10 minutes. After 2 quick rinses in PBS, each section was incubated 
with a filtered solution of 10% BSA in PBS for 30 minutes at RT. Each section was 
subsequently incubated overnight at 4ºC with the primary antibody diluted 1:100 in PBS 
in a humid chamber (primary antibodies used were mouse anti-GFP MAB3580 
[Chemicon Inc., UK], rabbit anti-GFAP G3893 [Sigma, Italy], anti-MAP2 AB5543 and 
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AB5622 [Chemicon Inc., UK] both diluted 1:100). Slides were washed 5 minutes in 
PBS, incubated for 30 minutes at RT in 0.3% Triton in PBS, then quickly washed 2 
times in PBS and incubated with secondary antibody for 3 hours at RT in the dark 
(FITC anti-mouse diluted 1:50 and Texas Red anti-rabbit diluted 1:100, both from 
Jackson Lab., USA). Slides were subsequently washed 2 x 10 minutes in PBS and 
incubated with 1µg/ml DAPI in PBS in the dark with agitation for 15 minutes to stain 
cell bodies (Sigma, Italy). The slides were quickly washed 3 times in PBS and mounted 
with a glass coverslip, using an aqueous mounting medium (Gel/mount, Biomeda). All 
the images were visualized with the Leica DMRA2 fluorescence microscope with the 
FW 4000 software (Leica, Italy) and captured with the Leica DFC300 FX video camera, 
maintaining the same parameters of acquisition for level of magnification, batch of 
animals and type and amount of virus injected. These images underwent a qualitative 
analysis (for GFP detection, emission of green fluorescence and for IHC studies 
emission of red or green fluorescence).  
Variations of this protocol were tested with the P2X7 primary antibody from 
Alomone (APR-004), using dilutions from 1:50 to 1:200, changing incubation times, 
solutions and secondary antibody but no staining was observed, opposite to what was 
reported in the literature (Kukley et al., 2004). 
 
3.2.7 Non radioactive in situ hybridization 
 
3.2.7.1 Probe preparation 
 
A digoxigenin labelled RNA probe targeting rat P2X7 was produced starting 
from a pcDNA3 (Invitrogen) plasmid carrying the 3540bp fragment derived from the 
EMBL submission X95882, having the addition of the EcoR1 linkers to both ends. 
After linearization of 5µg plasmid with the appropriate restriction enzyme (NcoI for the 
antisense probe [Promega] and SacII for the sense or control probe [New England 
BioLabs]) in a 30µl restriction mixture, the volume was increased to 200µl with water 
and then DNA solution was extracted with an equivalent volume of phenol, followed by 
2 extraction with chloroform/phenol (1:1 v/v). Plasmids were ethanol precipitated at -
20°C o.n., centrifuged at the maximum speed for 30min at 4ºC, dried for 15 min and 
dissolved in 10 µl of RNase-free water. These templates were used for the synthesis of 
digoxigenin labelled riboprobes, using the SP6/T7 DIG-RNA labelling kit (Boehringer) 
according to the manufacturer’s instructions. The probes were extracted with ethanol, 
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dissolved in 50µl sterile RNase free water (DEPC) with 1µl RNase inhibitor and stored 
at -80ºC in aliquots. 
 
3.2.7.2 Perfusion and tissue processing 
 
Adult Wistar-Han (300 grams roughly) rats were deeply anesthetized with a mix 
of ketamine 87mg/kg  and xylazine 13mg/kg and perfused through the ascending aorta 
first with a physiological solution followed by 4% PFA in phosphate buffer saline 
(PBS) pH 7.4 (Sigma, Italy). After perfusion, brains were removed from the cranial 
cavity, postfixed and cryoprotected at least overnight at 4ºC in a solution of 4% 
PFA/20% sucrose in PBS. Brains were stored at 4ºC in this solution up to 6 months. 
Brains were slowly frozen in isopentane at -80ºC and serial 40µm thick slices were cut 
at the cryostat (Leica). Free-floating sections were processed for in situ hybridization 
starting with a post-fization for 3hrs in 4% PFA/PBS at RT or were stored up to 12 
months in a solution of 4% PFA/PBS at 4ºC. 
To preserve the integrity of RNA probes and mRNAs in the tissue, all the 
solutions were prepared with ultrapure water (upH20) treated with 0.1% 
diethylpyrocarbonate for 6hrs (DEPC- upH20) and then autoclaved for 1hr at 120ºC. 
Glassware and pipette plastic tips and disposable plasticware were sterile or autoclaved 
for 1hr at 120ºC. Powder-free gloves were worn during all steps and were continuously 
changed.  
 
3.2.7.3 Hybridization 
 
Prior to the hybridization, slices underwent a permeabilization procedure carried 
out in polystyrene/polyester baskets (Sigma) inserted in 12-wells plastic tissue culture 
plates (Costar). Free-floating slices were washed twice in 0.1% tween 20 in 1 X PBS 
(PBST) at RT for 5min and quickly washed in H20, then the slices were permeabilized 
with 2.3% sodium-meta periodate (Sigma) in H20 at RT for 5min and quickly washed in 
H20. After this step, the sections were incubated in 1% sodium borohydride (Sigma) in 
0.1 M Tris-HCl buffer pH 7.5 at RT for 10min, washed twice in PBST for 3min at RT. 
Then the slices were digested with 8µg/ml proteinase K (Boehringer-Mannheim) in 
PBST at RT for 10-20min and washed twice in PBST at RT for 5min. After digestion 
the tissue sections were fixed in 4% PFA/PBS at RT for 5min and washed 3 times in 
PBST at RT for 10min. 
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Pre-hybridization was carried out at 55ºC for 60-90min in baskets inserted in 
plastic multiwell plates (12-wells, Costar) in the pre-hybridization solution containing: 
20mM Tris-HCl (pH 7.5), 1mM EDTA, 1x Denhardt’s solution, 300mM NaCl, 100mM 
dithiothreitol, 0.5mg/ml Salmon sperm DNA, 0.5mg/ml polyadenylic acid and 50% 
formamide (all reagents from Sigma, Italy). Slices were then transferred into the 
hybridization solution additioned with 10% dextransulphate and 50-100ng/ml 
digoxigenin labeled riboprobes. The riboprobes were added to the hybridization buffer 
with RNase-free pipette-tips to avoid the risk of RNAse degradation of the probes. In 
situ hybridization was carried out overnight (at least 16hrs) in multiwell plates at 55ºC 
without agitation. 
 
3.2.7.4 Post-hybridization and detection 
 
After hybridization the sections were washed twice in 2X saline sodium citrate, 
0.1% Tween 20 (SSCT)/50% deionized formamide at 55ºC for 30min, 20min in 2X 
SSCT at 55ºC and twice in 0.2 SSCT at 60ºC for 30min. Slices were then processed for 
immunodetection with an anti-DIG antibody F(ab)2 fragment conjugated with alkaline 
phosphatase (Boeringher, Italy), diluited 1:500 in PBST containing 10% fetal calf serum 
(FCS) at 4ºC overnight. After this incubation the sections were washed four times in 
PBST at RT for 10min, then incubated in the developing buffer (0.1M Tris-HCl buffer, 
0.1M NaCl, 0.05MM MgCl2 , 1mM levamisol) at RT for 5min and finally incubated in 
a cromogen solution composed by the developing buffer containing nitro blue-
terazolium (NBT) (Boehringer) and 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) 
(Boehringer, Italy). The reaction was generally carried out ON at 4ºC or for 2-6hrs at 
RT and was stopped by rinsing the sections in stop-solution (10mM Tris-HCl pH 8, 
1mM EDTA). Sections were then mounted in water on glass slides coated with 0.5% 
gelatin (Merck), dried for 30min in oven at 55ºC, then immersed 30sec in methanol, 
30sec in a mixture of methanol/xylene (1:1) and finally were immersed 3min in xylene 
and mounted in DPX-mount (BDH). 
 
3.2.8 Oligo radioactive in situ hybridization 
 
One oligonucleotide targeting rat P2X7 was selected from 3 different oligo 
sequences for radioactive in situ hybridization experiment in previous in house studies, 
since it produced the strongest and most specific signal. These sequences were designed 
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and checked with bioinformatics software and selected since they presented no or low 
potential hairpin formation, 3’ complementarity or potential self-annealing sites. Since 
the oligo concentration needed for the experiment is 150ng/µl, they were first diluted in 
H2O in order to generate the 10X stock and then diluted at the desired concentration for 
the experiment.  
For the radioactive labelling of the selected oligonucleotide with 33P-dATP, the 
enzyme terminal deoxynucleotidyl transferase (Invitrogen) was used after addition of 
the oligo (150ng/µl) and of the radioactive nucleotide (Perkin Elmer, USA). The 
reaction was then incubated 1-2 hours at 37°C. The labelled oligo was purified with the 
miniQuickSpin column (Roche, Italy) following the manufacturer’s instruction. To 
determine the amount of radioactive ligand incorporated, 1 µl of the purified solution 
was measured with the γ-counter instrument.  
For the hybridization experiment, the hybridization buffer (HB) was prepared in 
the following way: SSC 4X (Gibco), 50% deionized formamide, 1X denhardt solution, 
PBS 1X, tRNA 0.25 mg/ml, DTT 0.2M, dextrane solphate 0.1 g/ml, EDTA 10mM pH 
8, sarcosyl 10 mg/ml (all reagents from Sigma), ssDNA 0.5 mg/ml (Roche DNA-
Mbgrade) and water.  
For each animal 2 slides were used containing 4 brain slices each: the slides 
were prepared by cutting the frozen brain with a cryostat (Leica) with a slices width of 
14µm and then stored at -80°C until usage. For each slide 650 µl of HB containing the 
radioactive oligonucleotide were used. The final concentration of the radioactive oligo 
in the hybridization buffer was 5000 CPM/µl. The slides were incubated with the HB 
and radioactive oligo solution at 42°C ON, in a humid sealed chamber. After incubation 
and discard of the radioactive solution, the slices were washed 2 x 5 minutes in 2X SSC 
at RT, 3 x 20 minutes in 0.5X SSC at 55°C and 1 x 5 min 1X SSC at room temperature. 
Then they were dehydrated in ethanol solutions (EtOH): 2 minutes in EtOH 70%, 2 
minutes in EtOH 80% and 2 minutes in EtOH 95%. At the end the slices were air dried 
and exposed to a Fuji Imaging Plate for 20 days together with a 14C standard for the 
quantification. P2X7 mRNA level in the DG injected with the AAV- or Ad5-shRNA 
vectors, was quantified by image analysis software system AIS 4. 
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3.3 STATISTIC ANALYSIS 
 
Statistical analysis of the data was carried out using a one-way ANOVA and a 
Dunnett’s post-hoc test. Probability values less then 0.01 were considered significant.   
 
 
3.4 TAQMAN PRIMER AND PROBE AND OLIGO SEQUENCES 
 
P2X2: 
For GGACCTGGGAAGGCAGAGAC, 
Rev GGGCTAAAGCAAGACGCCTG, 
Probe TGTGACTGGGAAACAGAAACCTGTGCA. 
 
P2X4:  
For CCAACACCTCTCAGCTTGGATT, 
Rev GGTTCACGGTGACGATCATGT, 
Probe CAGCTCAGGAGGAAAACTCCCTCTTCATCAT. 
 
P2X7: 
For GCCCCTTATCAGCTCTGTGC, 
Rev CCTCCGTGACATTCTCTGTCAC, 
Probe CACCAAGGTCAAAGGCGTTGCAGA. 
 
Ad5 genome:  
Forward: TTG CGT CGG TGT TGG AGA,  
Reverse: AGG CCA AGA TCG TGA AGA ACC,  
Probe: CTG CAC CAC ATT TCG GCC CCA C .     
 
Oligo P2X7: 
5-CAT GTG CAA GAT CCA CTT GAT GGT GCC GTA ATT CAC GCT CTG  GAT 
C-3. 
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4. RESULTS 
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4.1 SHRNA GENERATION AND VALIDATION IN VITRO 
 
To suppress expression of rat P2X2, P2X4 and P2X7 receptors, four siRNA 
constructs for each target (named P2Xs-1 to 4) were designed using a commercial web 
algorithm (Ambion). These siRNAs were then screened for activity by cell transfection 
and TaqMan analysis. Initially, the rat pheochromocytoma PC12 cell line and a sub-
clone, PC12NS1, were selected, since the P2X2 and P2X4 receptors were reported to be 
expressed in both cells by TaqMan analysis, while P2X7 mRNA was detected only in 
the PC12NS1 cells. At first the PC12NS1 cells were transfected with the targeting 
siRNAs, using a positive control (Cy3-labelled siRNA against cyclophillin) and a 
negative control, i.e. a siRNA sequence designed not to anneal to any mRNA. The 
transfection was achieved with the Gemini surfactant GSK250910 with a modified 
version of the reverse transfection protocol (see the Material and Method section). After 
24 hours the transfection was repeated and 72 hours later the cells were lysed for 
TaqMan analysis. siRNA transfection efficiency was determined through evaluation of 
Cy3-labelled siRNA delivery using a fluorescence microscope. The transfection was 
repeated three times but in this first attempt no significant knockdown was detected, 
despite a 90% delivery of siRNAs into the PC12NS1 cells. In order to address this 
problem, PC12 cells were then transfected using the same conditions and different sets 
of TaqMan primers to evaluate P2X mRNA levels. These second set of primers were 
designed to amplify the mRNA region targeted by the siRNA, to facilitate the detection 
of P2X mRNA suppression. In the PC12 cells a maximum knockdown of P2X2 mRNA 
of 50% was detected with the P2X2-1 siRNA sequence and a maximum suppression of 
50% of P2X4 mRNA using the P2X4-1 sequence (Table 2). These results suggested that 
primer sequences used for evaluation of the mRNA level were critical and that it is 
important to use primers annealing near the siRNA targeted region. This may depend 
upon the fact that siRNA drives the degradation of the target mRNA starting from the 
annealing region. Flanking regions of the mRNA could still be present in the cell, even 
if not translatable, and detected by TaqMan analysis. The PC12NS1 cell transfection 
was then repeated and the target gene mRNA levels analyzed using the new TaqMan 
primer sets, but no specific gene suppression was detected. These results suggest a 
problem related to the type of cells used such as the potential presence of a less efficient 
RNA interference machinery. 
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Table 2. Level of P2X2 and P2X4 knockdown in PC12 cells compared to control after siRNA transfection 
(yellow pValue≤ 0.01 after ANOVA analysis). 
 
Since P2X7 and P2X4 expression is high in rat astrocytes, the siRNAs were then 
transfected into these primary cells, using the same delivery agent. As shown in Fig. 12 
good siRNA delivery was achieved (≈80% of cells transfected), measured by Cy3-
siRNACyclo delivery and good gene suppression (Table 3) one day following 
transfection. 
 
 
 
                                                                                                   
 
 
 
 
 
Fig. 12. Cy3-siRNA delivery in astrocytes 3 days after transfection with Gemini GSK250910, 3.5µg/ml 
(4x magnification). 
 
 
 
 
 
 
siRNA sequences in 
PC12 cells 
% Change 
from control 
P2X2-1 51 
P2X2-2 44 
P2X2-3 43 
P2X4-1 50 
P2X4-2 38 
P2X4-3 44 
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Table 3. % of P2XRs knockdown in astrocytes compared to control after siRNA transfection (yellow 
pValue≤ 0.01 after ANOVA analysis). 
 
This first analysis allowed active siRNA sequences to be identified. In order to 
achieve prolonged gene suppression in vivo, long term siRNA expression in the cell was 
obtained by using shRNA-expressing viral vectors since the shRNA is cleaved 
intracellularly to produce the active siRNA. As described in the Material and Method 
section, the shRNA cassettes were produced starting from the active siRNA sequence 
by cloning the double strand shRNA construct into the pENTR∆U6 plasmid, 
downstream of the human U6 promoter. Since previous in house studies have not 
always confirmed a correlation between the activity of siRNAs and shRNAs, the 
shRNA sequences were tested prior to constructing and producing the final shRNA-
viral vector. Hence the pENTR∆U6 plasmids, carrying the shRNA cassettes, were 
transfected into recombinant or co-transfected cells and astrocytes and the P2X mRNA 
levels determined by TaqMan analysis. 
Initially cell lines expressing both recombinant rat P2X4 and P2X7 receptors 
were transfected with the shRNA plasmids, using Gemini GSK30064 as the delivery 
agent. In the P2X4 recombinant cells the shRNA plasmid transfection was toxic, 
provoking a high level of cellular death. Significant gene suppression was observed in 
the P2X7 cells transfected with the shRNA-pENTR plasmid, albeit there was a certain 
level of cellular loss (Fig. 13, Table 4). The toxicity may suggest that recombinant cell 
lines are more sensitive to the transfection agents than normal cell lines. 
 
siRNA sequences 
in astrocytes 
% Change 
from control 
P2X4-1 33 
P2X4-2 39 
P2X4-3 60 
P2X7-1 7 
P2X7-2 49 
P2X7-3 6 
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Fig. 13. GFP expression in P2X7 (a) and P2X4 (b) recombinant cells 3 days after transfection with GFP 
encoding plasmid using GSK30064 8ng/ul (4x magnification). 
 
 
 
 
 
 
 
 
Table 4. % of P2X7 knockdown compared to control in HEK-P2X7 recombinant cells (yellow pValue≤ 
0.01 after ANOVA analysis). 
 
In order to resolve transfection induced toxicity in P2X4 and P2X7 recombinant 
cell lines, a co-transfection experiment was performed in a human cell line (HEK293A). 
The cells were transfected with the three different rat P2X receptor expressing plasmids 
and the pENTR-U6shRNA vectors at both 1:5 and 1:10 ratios. From previous in house 
studies the 1:10 ratio of target gene expressing vector/ shRNA vector was shown to be 
optimal to demonstrate mRNA suppression in a plasmid co-transfection experiment. In 
each ratio a high and statistically significant suppression of each target gene mRNA was 
achieved (Table 5).  
 
 
 
 
 HEK-P2X7 
Name of shRNA 
plasmids 
% Change from 
control 
P2X7-1 70 
P2X7-2 76 
P2X7-3 13 
P2X7-4 17 
P2X4 P2X7 ba 
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HEK-P2XRs 
ratio 1:5 
HEK-P2XRs  
ratio 1:10 
name of shRNA 
plasmids 
% Change from 
control 
% Change from 
control 
P2X2-1 99 100 
P2X2-3 81 86 
P2X2-4 97 99 
P2X4-1 92 94 
P2X4-3 91 95 
P2X4-4 89 91 
P2X7-1 98 62 
P2X7-2 100 65 
P2X7-3 100 96 
P2X7-4 100 99 
 
Table 5. % of P2XRs knockdown compared to control in HEK co-transfected cells (yellow pValue≤ 0.01 
after ANOVA analysis). 
 
To evaluate siRNA activity in cells endogenously expressing P2X receptors, plasmid 
transfection of PC12 cells and astrocytes was optimized for the delivery of a GFP 
expressing reporter plasmid, testing 11 different kinds of in house prepared cationic 
surfactants as well as the commercial Lipofectamine 2K (LP2K). Each type of cell was 
transfected with different amounts of the various cationic agents, at different cell 
densities. Using GFP fluorescence as a marker of transfection, only low levels of 
transfection efficiency was achieved with all type of surfactants in both PC12 cells and 
astrocytes. LP2K was the best delivery agent (Fig. 14), but a certain amount of toxicity 
was detected by cellular morphology visualization. 
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Fig. 14. a: GFP plasmid delivery in PC12 cells with GSK347232A 10ng/ul after 3 days. b: GFP plasmid 
delivery in astrocytes with LP2K 1.5ng/ul after 3 days (4x magnification).                                                                                     
 
70% DNA delivery with good cell viability of astrocytes was achieved with an 
alternative technique, the AMAXA system. Rat astrocytes were transfected with the 
pENTR∆U6-shRNA plasmids. Using TaqMan analysis a significant suppression of 
P2X4 and P2X7 receptor mRNA was detected in each experiment 3 days after 
transfection (Table 6). P2X2 mRNA expression was below the level of detection in 
these primary cells. The experiment was then repeated obtaining slightly different 
results that could be explained by the variability between different batches of primary 
cells. 
 Astrocytes:experim.1 Astrocytes:experim.2 
Name of shRNA 
plasmids 
% Change from 
control 
% Change from 
control 
P2X7-1 70 36 
P2X7-2 8 13 
P2X7-3 32 40 
P2X7-4 62 0 
P2X4-1 37 68 
P2X4-3 69 75 
P2X4-4 49 60 
 
Table 6. P2X7 and P2X4 knockdown compared to control in astrocytes transfected with the pENTR-U6-
shRNA plasmids after 3 days (yellow pValue≤ 0.01 after ANOVA analysis). 
 
Since the purpose of this study was to achieve the functional suppression of P2X 
receptors through RNAi, the level of target protein after siRNA delivery needed to be 
a b
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evaluated. In line with that, a number of commercial antibodies for rat P2X2, P2X4 and 
P2X7 proteins were tested by Western blot analysis with the specific recombinant or co-
transfected cell lysate to select the most appropriate for quantification. The selected 
antibody was then evaluated on cell lysates from rat hippocampal neurons, rat 
astrocytes, PC12, PC12NS1, P2X4 and P2X7 recombinant cells or P2X2 plasmid 
transfected cells using membrane or nuclear fractions (see Fig. 15).  
 
 
Fig. 15. P2X2 (a), P2X4 (b) and P2X7 (c) protein detection in PC12, PC12NS1, P2X4 and P2X7 
recombinant HEK293, P2X2 transfected HEK293, hippocampal neurons and astrocytes membrane or 
nuclei fraction (the arrow indicates the band and the size corresponding at the P2X protein). 
 
In this assay P2X2 protein was detected only in the HEK293A co-transfected cells 
while P2X4 protein was detected in recombinant cells, astrocytes and at lower levels in 
PC12 and PC12NS1 cells. P2X7 protein was detected in recombinant cells and in both 
hippocampal neurons and astrocytes but multiple bands were detected in the primary 
cells. The selected antibodies were then used to assay protein knockdown in the 
c MM   m   m   m m   nu nu 
Pc12 Pcns1 Hek4 Hek7 Pns1  Hek7  Hippo Astro
m   m
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Legend: 
MM: molecular marker 
m: protein membrane fraction 
nu: protein nuclear fraction 
Pc12: PC12 cell line 
Pcns1: PC12NS1 cell line 
Hek4: P2X4-HEK29A recombinant cells 
Hek7: P2X4-HEK29A recombinant cells 
P2X2: P2X2-HEK29A transfected cells 
Hippo: hippocampal neurons 
Astro: rat astrocytes 
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HEK293A co-transfection experiment (Fig. 16). This experiment was repeated twice but 
the results were variable and not clearly interpretable (data not shown). These results 
showed that the antibodies selected for Western blot analysis were not adapted to 
quantify target protein suppression. 
 
 
 
 
 
 
 
 
 
 
  
Fig. 16. P2X2, P2X4 and P2X7 protein detection with the relative tubulin expression in P2Xs co-
transfected HEK293. The level of tubulin was determined to normalize sample loading [Legend: NC: 
negative control (shRNA not targeting plasmid), PC: positive control (with only P2Xs plasmid), Xs-1 to 
4: pENTR-shRNA plasmids]. 
 
From the previous results, the most active shRNA sequences identified for each 
target gene were as follows: P2X2-1 and P2X2-4 for P2X2, P2X4-1 and P2X4-3 for 
P2X4 and P2X7-1 and P2X7-4 for P2X7. These shRNA constructs were then tested for 
their specificity by their ability to suppress expression of the cognate gene but not of the 
two other P2X genes. HEK293A cells were co-transfected with each P2X expression 
vector and the selected shRNA vector, using P2X vector/ shRNA vector ratios of 1:1, 
1:2 and 1:10, maintaining the total amount of DNA for each ratio constant. For the 1:1 
and 1:2 ratios, an shRNA vector against an unrelated rat gene (diamine oxidase, DAO) 
was also co-transfected as a positive control. From these experiments a non-specific 
suppression with a few of the shRNA sequences was detected at a 1:10 ratio, where the 
amount of shRNA plasmid was 10-fold higher than the P2X expressing plasmid. In 
particular a significant and non-specific suppression of P2X2 mRNA with the P2X7-4 
shRNA plasmid and of P2X7 mRNA with the P2X4-3 shRNA plasmid was detected. 
Regions of homology between the shRNAs and mRNA sequences were investigated, to 
P2X7 
NC      PC    X7-1    X7-2   X7-3    X7-4
tubulin 
P2X2 
NC         PC       X2-1    X2-3    X2-4 
tubulin 
P2X4
  NC         PC      X4-1    X4-3     X4-4 
tubulin
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test if part of the 19 bases of shRNA sequences can anneal to non-target mRNAs. Up to 
9 nucleotides of homology were detected in some of the shRNA sequences for non 
targeted P2X receptor genes, but no correlation between the amount of homology and 
the level of non-specific effect was found. Therefore these results can best be explained 
by non-specific gene suppression caused by increasing amounts of shRNA plasmid 
compared to gene expressing plasmid. The experiment above gave inconsistent results 
since the same non-specific mRNA suppression was not detected in all 3 ratios of 
P2Xs/shRNA plasmid co-transfection. Moreover the co-transfection experiment is an 
artificial system since the P2X genes are not endogenously expressed in the HEK293A 
cell line. In order to determine the shRNA specificity for endogenously expressed P2X 
genes, the shRNA plasmids were transfected into astrocytes, using 2 and 5µg of shRNA 
plasmids. No significant non-specific effects were measured for P2X4 and P2X7 (Table 
7).  
Astrocyte pENTR-U6 shRNA transfection 
P2X4-2ug 
shRNA vectors 
% Change from 
control 
P2X4-5ug 
shRNA vectors 
% Change from 
control 
DAO 0 DAO 40 
P2X2-1 0 P2X2-1 20 
P2X2-4 0 P2X2-4 23 
P2X4-1 44 P2X4-1 57 
P2X4-3 66 P2X4-3 72 
P2X7-1 0 P2X7-1 33 
P2X7-4 0 P2X7-4 20 
P2X7-2ug 
shRNA vectors 
% Change from 
control 
P2X7-5ug 
shRNA vectors 
% Change from 
control 
DAO 20 DAO 38 
P2X2-1 0 P2X2-1 0 
P2X2-4 0 P2X2-4 0 
P2X4-1 0 P2X4-1 0 
P2X4-3 0 P2X4-3 0 
P2X7-1 54 P2X7-1 58 
P2X7-4 23 P2X7-4 30 
 
Table 7. % of P2X4 and P2X knockdown compared to control in “nucleofected” astrocytes (yellow= 
pValue≤ 0.01 after ANOVA analysis, red= specific shRNA vectors). 
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4.2 VIRAL VECTOR VALIDATION IN VITRO 
 
Since the purpose of this study was to assess the ability of RNA interference to 
suppress P2X7, P2X2 and P2X4 gene expression in vivo, viral vectors containing a U6-
shRNA cassette were constructed, starting from U6-shRNA plasmids screened in 
cultured rat astrocytes and HEK293 cells. Previous in house in vitro studies indicated 
that AAV2/6 and Ad5 viruses preferentially infect neurons and glia, respectively. Hence 
the AAV2/6 virus was chosen to deliver the P2X2, P2X4 and P2X7 shRNA cassettes to 
neurons and the Ad5 virus to deliver the P2X7 shRNA cassettes to glia. These AdV and 
AAV viral vectors were then evaluated for their ability to suppress P2X expression in 
vitro after infection of rat astrocytes and hippocampal neurons, respectively, through 
TaqMan analysis, Western blot and ion channel activity studies. Different amounts of 
virus and different post-infection time points were tested.  
Two different Ad5-shRNA vectors targeting P2X7 were produced in house. The 
Ad5 viral vectors, Ad5-P2X7-1 and Ad5-P2X7-4, were validated by infection of rat 
astrocytes at multiplicity of infection (moi) of 5, 50 and 500, which represents the ratio 
of virus particles per cell. Since the Ad5 vectors do not express a reporter gene, some 
astrocytes were infected with a GFP expressing Ad5 vector to measure the level of 
infection. A high level of GFP expression was observed under fluorescence microscopy 
in each condition analyzed (see Fig. 17 for an example of infected cells). The P2X7 
mRNA levels were assessed 48 hours, 72 hours and 5 days post-infection. P2X4 mRNA 
levels were also measured at the same time points to evaluate possible non-specific 
effects of the vectors. As a negative control, an Ad5 vector expressing the shRNA 
sequence designed not to anneal to any mRNA was used. Ad5-P2X7-4 was the most 
active and specific vector, achieving a statistically significant maximum suppression of 
80% of P2X7 mRNA compared to the negative control at moi 50 after 5 days. P2X4 
mRNA level was not modified by the P2X7 viral vectors, indicating the specificity of 
viral-mediated gene suppression (Table 8). Measuring the level of GAPDH, some toxic 
effects were seen with the higher moi, as expected, particularly after 5 days. The 
experiment was repeated with similar results (data not shown).  
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 Time point 48hrs Time point 72hrs Time point 5ds 
AdV5 P2X7%kd P2X4%kd P2X7%kd P2X4%kd P2X7%kd P2X4%kd 
X7-1 moi 5 15 21 37 0 47 0 
X7-4 moi 5 18 3 47 0 33 0 
X7-1 moi 50 46 0 56 0 62 0 
X7-4 moi 50 54 10 67 0 80 0 
X7-1 moi500 59 8 65 0 46 0 
X7-4 moi500 63 4 42 0 0 0 
 
Table 8. % of P2X7 mRNA knockdown after Ad5-P2X7-1 and Ad5-P2X7-4 infection, compared to Ad5 
negative control (6 replicates in a 96 wells plate for each condition were used) [yellow: significant 
knockdown after ANOVA analysis (pValue≤ 0.01), red: selected virus]. 
 
 
Fig. 17. GFP expression in rat astrocytes after Ad5-GFP infection (50 moi, 72 hrs from infection) (10x 
magnification). 
 
Western blot analysis was run to determine if P2X7 protein also decreased after Ad5-
shRNA infection. Astrocytes were infected with moi 10 and 100 of the same two 
targeting vectors as above and the negative control vector. Whole cell lysate was 
collected after 4 days. With 10 moi of the Ad5-P2X7-4 virus, an approximately 60% 
decrease in P2X7 protein was observed, which was not statistically significant, while 
the level of P2X4 was unchanged (Fig. 18). The experiment was then repeated but 
protein reduction was not observed, demonstrating that this antibody in the Western blot 
and in these experimental conditions is not reliable for protein quantification. As 
previously shown, staining with the selected antibody for P2X7 in astrocytes revealed 
several bands, some of which non-specific, and two more intense bands of 
approximately 70 and 79kDa, probably related to different glycosylated forms of the 
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protein. A similar staining pattern was reported with a different anti-P2X7 antibody in 
rat hippocampal membrane fraction (Kim et al., 2001). This antibody was also tested in 
immunocytochemistry (ICC) staining of rat astrocytes. Despite very strong GFAP 
staining, a marker of astrocytes, no staining was detected with the anti-P2X7 antibody 
(Fig. 19). This might have been due by the very low P2X7 expression in individual 
cells. As previously described, the specificity of the antibody used was questioned due 
to the observation of a signal in the protein fraction from brains of knock-out animals 
(Sim et al. 2004).  
 
 
 
 
 
 
 
 
 
 
Fig. 18. P2X7 Western blot analysis and P2X7 quantification from AdV infected astrocytes: 2 wells of a 
24 wells plate were infected with 10 or 100 moi of the Ad5 vectors. The level of tubulin was determined 
to normalize sample loading (the two brighter bands are between 60 and 80kDa, the first line represents 
the molecular marker, N represents the negative control and X7-1 and X7-4 the two targeting vectors). 
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Fig. 19. GFAP staining in rat astrocytes (10x magnification). 
 
To overcome the problem of protein quantification, an assay to measure P2X7 
receptor function was set-up. Chakfe and colleagues reported that P2X7 activation in 
microglial cells provokes IL-1ß release after LPS stimulation (Chakfe et al., 2002). 
Microglial cells were infected with the different vectors and then treated with the 
selective agonist BzATP (300µM) or ATP. IL-1ß levels were quantitated with an 
ELISA assay. The cells were first infected at moi 100 and 200 of Ad5-P2X7-1 and Ad5-
P2X7-4 and 48 hours later were treated with 1µg/ml LPS. 24 hours afterwards, the 
assay was performed. The results are summarized in Fig. 20.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20. IL-1ß ELISA results (n= 6) (HBSS= saline solution, QNSC= negative control). 
 
A statistically significant decrease in LPS stimulated IL-1ß release in the cells infected 
with Ad5-P2X7-4 compared to the negative control was measured (Table 8). However, 
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as shown in the graph, an expected toxic effect was observed after viral infection. This 
preliminary experiment should be repeated with a lower moi of the viral vectors but 
unfortunately this was not possible due to the unavailability of rat primary microglial 
cells. 
Ad5 % IL1β kd 
X7-1 100moi 0 
X7-4 100moi 49 
X7-1 200moi 0 
X7-4 200moi 31 
 
Table 9. IL-1ß kd (yellow: pvalue ≤ 0.01 after ANOVA analysis) 
 
AAV2-based plasmids carrying the shRNA cassettes for the P2X receptors were 
constructed in house and then packaged into AAV6 capsids by the University of 
Pennsylvania for generation of high titer of viral vector stocks. The two AAV2/6 
vectors targeting P2X2, the three vectors targeting P2X4 and the four vectors targeting 
P2X7 were screened on cultured rat hippocampal neurons. After 7 days in vitro (DIV) 
the cells were infected with two different amounts of each virus, 5x103 viral genome 
copies per cell (gc/cell) and 5x104 gc/cell. Five days later the RNA was extracted and 
P2X gene expression was quantified by TaqMan. Since these vectors expressed GFP, it 
was possible to quantify the efficiency of viral infection from fluorescence microscopy 
(Fig. 21).  
 
Fig. 21. GFP expression in rat hippocampal neurons after 5 days from infection (5x104 gc/cell) (10x 
magnification). 
 
 
 
 83
 
This first experiment identified the most potent and specific viral vector to 
suppress target gene expression. The vectors AAV-P2X2-3, AAV-P2X4-3 and AAV-
P2X7-3 were selected with a maximum target mRNA knockdown of 90%, 90% and 
83%, respectively, which was statistically significant compared to the negative control, 
without affecting the expression of the other P2X genes (Table 10).  
 
 % P2X2 knockdown % P2X4 knockdown % P2X7 knockdown 
 5x10
4 
gc/cell 
5x103 
gc/cell 
5x104 
gc/cell 
5x103 
gc/cell 
5x104 
gc/cell 
5x103 
gc/cell 
AAV-P2X2-3 89 87 0 0 0 0 
AAV-P2X2-4 94 84 18 0 19 40 
AAV-P2X4-1 15 27 74 7 0 0 
AAV-P2X4-3 0 0 89 18 31 0 
AAV-P2X4-4 0 0 58 0 0 0 
AAV-P2X7-1 0 25 2 0 51 64 
AAV-P2X7-2 28 17 3 0 66 67 
AAV-P2X7-3 0 0 12 0 83 59 
AAV-P2X7-4 0 0 11 0 22 34 
 
Table 10. AAV vectors screening in rat hippocampal neurons for P2X knockdown: 4 wells of a 24 wells 
plate were infected for this analysis (yellow: pvalue ≤ 0.01 after ANOVA analysis, red: selected virus). 
 
These vectors were tested again on cultured rat hippocampal neurons at 7 DIV at 5x104 
gc/cell. Four days and five days after infection RNA was isolated for TaqMan analysis 
and the total protein content was extracted for Western blot. TaqMan results were 
consistent with the previous experiment (Table 11).  
 
 % Change from control 
AAV 
5x104gc/cell-4d 
P2X2 P2X4 P2X7 
P2X2-3 56 6 0 
P2X4-3 0 76 0 
P2X7-3 0 16 22 
 
Table 11. P2X knockdown data validation with selected AAV virus (yellow: pvalue ≤ 0.01 after ANOVA 
analysis). 
 
Some variability between the data, in particular for the P2X7 targeting vector, was 
observed, which might be explained by the different time points tested, by a certain 
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variability between different hippocampal neuronal cultures and a differential sensitivity 
to viral vector infection. The results from the Western blot were not unequivocal and 
reliable (Fig. 22).  
 
 
 
Fig. 22. P2XR Western blot analysis from AAV infected neurons, 5x10e4 gc/cell, 5d post-infection: 2 
wells of a 24 well plate were used for this analysis. The level of tubulin was determined to normalize 
sample loading (the first line represents the molecular marker, NSC: negative control virus, Xs-3: 
shRNAs viral vectors). 
 
In particular multiple bands were detected in the P2X7 Western blot. The 70 and 79KDa 
bands were reported also by Kim and colleagues but only the 79KDa band was detected 
in all the samples (Kim et al., 2001). After normalization with tubulin, the P2XRs 
signals were quantified but no significant protein suppression was measured. Moreover 
the experiment was repeated with the same samples and a different pattern of staining 
was detected. This indicates that the antibodies available cannot be used for a reliable 
quantification of the target protein levels. An ICC experiment was also run with 
80 KDa 
P2X2 protein after AAV-shRNA infection
60 KDa 
tubulin 
P2X4 protein after AAV-shRNA infection
60 KDa 
tubulin 
80 KDa 
P2X7 protein after AAV-shRNA infection
80 KDa 
60 KDa 
tubulin 
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cultured hippocampal cells, but while good staining was detected with the neuronal-
specific ß3-tubulin antibody (Fig. 23), no staining was seen with the P2X antibody. This 
could reflect the low level of P2X expression in cultured neurons derived from embryos 
and the low sensitivity of the antibodies used. No functional assays were available in 
house to measure P2XRs activity in hippocampal neurons infected with the AAV-
shRNA vectors. 
 
 
 
 
 
 
 
 
 
Fig. 23. ß3-tubulin staining of cultured hippocampal neurons (10x magnification). 
 
Specific AAV2/6-shRNA vectors each for P2X2, P2X4 and P2X7 were 
identified at the end of these in vitro experiments together with one active and specific 
Ad5 vector suppressing P2X7 mRNA expression. 
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4.3 VALIDATION OF VIRAL VECTORS IN VIVO 
 
Since the objective of this study was to down-regulate rat P2X receptors in vivo, a 
procedure for shRNA-viral vectors injection into rat brain was optimized. In view of the 
fact that the strongest patho-physiological evidences of involvement in depression were 
linked to P2X7, the main focus of the in vivo work regarded both AAV- and Ad-shRNA 
vectors targeting P2X7. The viral vectors were injected into rat hippocampus through a 
neurosurgical procedure using a stereotaxic device with a microinfusion pump 
connected to a home-made borosilicate needle. These needles were used because their 
tips have extremely small external diameter in order to minimize tissue damage. The 
outer diameter of the tip is roughly 30-50µm while the tip of the more commonly used 
steel needles measure 200-400µm. This characteristic of the glass needles leads to a 
negligible amount of mechanical damage at the injection site, with subsequent necrosis 
and inflammation. This is of particular importance when injecting viral vectors, which 
can themselves induce an immunological response. Moreover, when investigating gene 
suppression, it is important to limit external insults that can confound interpretation of 
the results. In line with that, this system allows the viral vector to be injected into a 
specific brain area, in this case the dentate gyrus (a subregion of the hippocampus) with 
high precision and without damaging the brain tissue. The dentate gyrus was selected 
since it was reported that P2X7 mRNA is expressed throughout the cell body layers of 
the hippocampus, including the stratum pyramidale in the CA1 and CA3 regions and the 
granule cell layer (GC). In addition, P2X7 immunoreactivity was observed in the 
polymorphic layer (PL) of the dentate gyrus (Sperlagh et al., 2002). This area is of 
particular relevance in psychiatric disorders since the hippocampus, which is part of the 
limbic system, is involved in emotional control, in learning and memory processes and 
is believed to play a key role in the patho-physiology of both unipolar and bipolar 
disorders.  
Initially a pilot experiment using several animals was performed, in order to 
optimize the operator experience with the neurosurgical procedure and to determine the 
exact coordinates for the different injection sites by infusing a physiological solution 
containing Trypan blue, a colour marker. The coordinates of injection were calculated 
from bregma according to “A Stereotaxic Atlas of the Rat Brain” [Pellegrino et al., (2nd 
edition), 1979]. From visualization of Trypan blue in brain slices, it was found that the 
coordinates of injection chosen were correct and that small differences in animal weight 
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(200-250 grams) did not alter the position of the injection area in the animal (data not 
shown). 
The AdV vector was initially deeply characterized in vivo due to the unavailability 
of the AAV-shRNA vectors. An injection experiment with Ad5 vectors was performed 
to evaluate the ability of the viral vector to infect glial cells and to suppress P2X7 
mRNA expression in vivo. Figure 24 shows the experimental design.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 24. Ad5 in vivo experiment plan. 
 
Each rat received unilateral infusions of vector or saline at a rate of 0.2 µl/min for a 
total volume of 4µl and a total amount of 1x108 plaque forming units (pfu) for each 
injection. The amount of virus injected was in line with similar Ad5 experiments in vivo 
in the literature, which reported no immunological response in the rat brain (Xia et al., 
2002 and Shine et al., 1997). This experiment was designed to determine if the targeting 
viral vector, Ad5-P2X7-4, could suppress P2X7 mRNA and protein expression 
compared to the control vector. Both the dorsal and ventral dentate gyrus were injected 
to achieve shRNA-virus diffusion in the whole hippocampus. For TaqMan analysis, 
some of the animals were unilaterally infused with the targeting vector, Ad5-P2X7-4, or 
the negative control vector, Ad5-QNSC, while other animals were infused only with 
saline. Two animals per time point were also included as non-operated controls. In 
addition, quantification of the viral genome in all the injected hippocampi was 
performed as a positive control for viral vector infusion. Since the Ad5 vectors do not 
express a marker gene, two animals per group were infused with the Ad5-GFP 
Ad5-Immuno  
Ad5-GFP (n=2) Ad5-QNSC (n=3) Ad5-P2X7-4 (n=3)
2 and 4 weeks 
Ad5-TaqMan 
Saline (n=3) Ad5-QNSC (n=4) Ad5-P2X7-4 (n=4)
2 and 4weeks 
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expressing vector in order to qualitatively evaluate the anatomical specificity of the 
infection in these animals through analysis of GFP fluorescence. Two time points were 
chosen (2 and 4 weeks post-infusion) to investigate target gene suppression and viral 
vector expression in vivo. Following viral vector infusion, the hippocampi were isolated 
and processed as described in Materials and Methods. Ad5 genome quantitation in the 
samples infused with the Ad5-P2X7-4 and Ad5-control vector is shown in Fig. 25.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 25. Ad5 copy number in hippocampi 2 and 4 weeks following infusion in vivo with Ad5-P2X7-4 and 
Ad5-QNSC vectors. 
 
A much higher viral copy number was detected in the hippocampi isolated 2 weeks after 
viral vector injection, compared to those isolated at 4 weeks. Since these vectors do not 
replicate and do not integrate into the host genome, the much lower levels of Ad5 
genome at 4 weeks might be due to dilution of virus in astrocytes undergoing cell 
replication. The variability between samples was probably caused by the infusion 
technique. Since the injection needles can be clogged due to the small diameter of the 
tip and the high opposing pressure in the tissue, this might have led to different amounts 
of virus injected in each animal. 
Taqman analysis of P2X7 mRNA was performed on all the hippocampi. 
Expression levels were compared between the injected ipsilateral side and the non-
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injected contralateral side from the same animal and between Ad5-P2X7-4 and Ad5-
QNSC injected animals to determine if gene expression changed. No significant 
decrease in P2X7 expression was observed in the hippocampi infused with the Ad5-
P2X7-4 compared to the negative control, as initially expected from the in vitro results 
(Fig. 26). An elevated variability in some of the groups was observed, in particular in 
the Ad5-P2X7-4 injected samples at 2 weeks, probably due to the normal variability 
between different animals and to the low number of animals analyzed (n=4). Since 
different amounts of viral vector were detected in each sample, the P2X7 mRNA level 
was also normalized for the amount of viral genome injected, but no significant 
decrease was measured after normalization. As a control for specificity, P2X2 mRNA 
levels were also measured, with no significant difference among the samples (data not 
shown). No evidence of RNA degradation, which could have affected RNA levels 
during the analysis ex-vivo, was observed from qualitative and quantitative analyses 
(data not shown). 
 
 
 
 
Fig. 26. P2X7 mRNA level 2 and 4 weeks following Ad5 vectors injection in rat hippocampus (GAPDH 
was used to normalize P2X7 mRNA level). 
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The brains from animals injected with a GFP-containing viral vector and 
sacrificed 2 and 4 weeks after injection were processed for direct GFP visualization 
with fluorescence microscopy and IHC using anti-GFP and anti-GFAP antibodies. GFP 
fluorescence was localized in both the injection sites (dorsal and ventral DG) with low 
or no diffusion into the sorrounding areas (CA3, CA2, and CA1) and with no 
fluorescence in the controlateral hippocampus as expected (Fig. 27 and 29). Staining 
with an anti-GFP antibody confirmed these results (Fig. 28 and 29). The staining was 
observed for roughly 0.8-1 mm across the injection area in the rostro-caudal axis.  
 
                                                   
Fig. 27. GFP fluorescence in dorsal DG (a, c) and ventral DG (b, d) 2 and 4 weeks after hippocampal 
infusion with Ad5-GFP (in the circle is indicated the DG area) (5x magnification). 
a 
d 
b 
c 
b
a b
 91
 
Fig. 28. Dorsal and ventral hippocampus injected with Ad5-GFP after 2 weeks (a, b) and after 4 weeks (c, 
d) stained for GFAP (red), GFP (green), and DAPI (blue) (10x magnification).   
    
 
Fig. 29. Dorsal hippocampus ipsilateral (a) and contralateral (b) and ventral hippocampus ipsilateral (c) 
and contralateral (d) stained for GFP (green), GFAP (red) and DAPI (blue) 2 weeks after Ad5-GFP 
injection (5x magnification). 
                                                   
Specific to the ipsilateral side, GFP-stained cells showed typical morphology of 
astrocytes (Fig. 31), while few labelled neurons were seen (Fig. 30). A certain level of 
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GFAP co-localization with GFP staining was observed (Fig. 31) even if the thickness of 
the slice (30µm) did not permit resolution of single cells.  
 
 
Fig. 30. GFP stained cells looking like neurons in ventral DG pointed by the white arrows (20x 
magnification). 
 
 
Fig. 31. GFP and GFAP staining in the ventral hippocampus (circled cells indicate GFP and GFAP co-
localization) (60x magnification). 
 
From a qualitative observation of the GFAP stained slices, no significant 
difference in the staining level in the ipsilateral hippocampus compared to the 
controlateral side was detected, thus excluding astrocytosis provoked by the viral 
injection (Fig. 32). On the contrary, a lower level of GFP expression was seen in the 
brains of animals sacrificed 4 weeks after injection compared to the brains of animals 
sacrificed after 2 weeks (Fig. 27, 28). These results confirm the previous TaqMan 
quantification of the adenoviral genome at the different time points. Unfortunately it 
was not possible to stain the slices for P2X7, because the commercial antibody did not 
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give clear staining even after trying several antibody concentrations and incubation 
analysis. 
 
 
Fig. 32. Contralateral (a) and ipsilateral (b) dorsal hippocampus infused with Ad5-GFP and stained for 
GFAP (5x magnification). 
 
As previously seen, P2X7 mRNA quantification by TaqMan did not show gene 
suppression after Ad5-shRNA injection. This result could be explained by the restricted 
localization of the viral genome in the hippocampus and therefore the impossibility to 
detect gene suppression when the whole tissue was analyzed. Another pilot study was 
carried out in order to optimize viral injection by increasing the volume of virus injected 
and changing the depth of infusion maintaining the same viral titer of the previous 
study. A total of 6µl of Ad5 vector was injected into the DG at a rate of 0.3µl/min at 2 
different depths of injection (3µl at the maximum depth and 3µl at + 0.3mm). This 
protocol of injection was chosen to maximize the viral diffusion in the injected area. 
Moreover the Ad5-shRNA vectors were co-injected with the Ad5-GFP virus to 
qualitatively evaluate the injection. Using this different protocol, a higher level of viral 
diffusion compared to the previous study was observed in the injected area and GFP 
expression was confirmed mainly in astrocytes and at lower level in neurons (Fig. 33).  
 
a b 
b
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Fig. 33. GFP expression after Ad5-GFP injection in DG at 2 different depths of infusion (1x108 pfu) (10x 
magnification). 
 
The first AAV2/6-P2X7 viral vector injection was also completed. In this 
experiment 2.7x109gc of AAV vectors was injected into the hippocampus with the 
injection protocol described above for the Ad5 injection. The amount of virus injected 
was similar or slightly lower to that reported in the literature (see Babcock et al., 2005 
and Cao et al., 2004). In any case this was the maximum possible amount of injected 
virus since the viral titer for both the targeting and negative AAV vectors was quite low. 
In fact the yields of the AAV2/6 vectors are usually 10 fold lower than the ones of other 
serotypes. In addition it is not recommended to inject more than 4μl for each injection 
point to avoid provoking tissue damage. The AAV injected animals were sacrificed 4 
weeks post-injection since the AAV vectors require longer time than Ad5 vectors for 
maximum transgene expression in vivo. The microinfused brains were analyzed for GFP 
fluorescence and GFP immunoreactivity (GFP-IR), since the AAV vectors co-expressed 
GFP. GFP-IR was detected in both the granular cell layers and the polymorphic layer of 
the DG (Fig. 34a). A lower level of GFP expression was also detected in the 
surrounding areas as in the pyramidal neurons of the CA1, CA2 (Fig. 35a) and CA3 
regions and in the mossy fibers (Fig. 35b). No GFP staining was detected in the 
controlateral non-injected hippocampus (Fig. 36). The group of GFP-expressing 
neurons were spread over 1–2 mm on a rostro–caudal axis consistent with what reported 
in the literature (see Babcock et al., 2005). From a co-localization study with the 
neuronal marker MAP2, GFP was detected in neurons both in the cell body and in the 
projections (Fig. 34b, 37 and 38). Other slices from the same brains were also stained 
with the anti-GFAP antibody, a marker of astrocytes, to analyse if there were gross 
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differences between the injected hemisphere and the non-injected controlateral 
hemisphere, thus excluding the presence of astrocytosis induced by viral vector 
injection. No significant differences in GFAP staining were observed after viral 
injection. These results confirm the previously observed in vitro tropism of the AAV2/6 
viruses for neurons.  
 
 
 
 
 
 
 
 
 
Fig. 34. a: GFP detection in dorsal DG 4w after AAV2/6 injection (10x magnification). b: IHC analysis in 
dorsal AAV injected DG for GFP (green), MAP2 (red) and DAPI (blue) (10x magnification).  
 
 
Fig. 35. a: GFP expression in CA1 and CA2 regions after AAV2/6 injection (10x magnification). b: GFP 
expression in CA3 region after AAV2/6 injection (10x magnification). 
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Fig. 36. Controlateral DG after AAV2/6 injection (10x magnification).  
 
Fig. 37. GFP detection in GC after AAV2/6 injection (20x magnification).  
 
Fig. 38. GFP-MAP2 staining in DG cells injected with AAV after 4 weeks (green: GFP, red: MAP2, 
yellow: co-localization) (20x magnification). 
 
In order to determine if P2X7 gene expression was reduced around the injection 
site, in situ hybridization was performed. Both AAV- and Ad5-shRNA injected brains 
were processed for colorimetric in situ hybridization to quantify P2X7 mRNA directly 
in the injected area. A non-radioactive colorimetric in situ hybridization protocol was 
performed with a digoxigenin labelled P2X7 riboprobe. Unfortunately, even if a specific 
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signal was detected with the antisense probe in the pyramidal and granular cell layer, it 
was not possible to sufficiently reduce the background signal to accurately quantify 
mRNA expression, a problem often reported with this technique. Moreover a high level 
of tissue degradation was observed after the hybridization due to the experimental 
conditions used (Fig. 39).  
 
 
Fig. 39. Dorsal rat hippocampus stained with a digoxigenin-labelled riboprobe for rat P2X7 (left) and 
with a control sense probe (right): the arrow indicates the presence of the stain or not in the pyramidal cell 
layer (5x magnification). 
 
Consequently, radioactive in situ hybridization was used. Since this method 
requires a different sample processing ex-vivo, another in vivo injection study was 
performed. Six animals were injected with the AAV2/6- or Ad5-shRNA targeting 
vector into the dorsal dentate gyrus of one hemisphere and with the negative control 
virus in the other hemisphere. The Ad5-GFP virus was co-injected with the Ad5-shRNA 
vectors in order to detect the presence of the adenoviruses in the injected area. After 4 
and 2 weeks respectively following injection of the AAV and the Ad5 vectors, the 
brains were isolated, frozen and cut into 14µm slices. 8 slices from each animal 
corresponding to the injected area (dorsal DG) were selected for GFP visualization prior 
to the in situ hybridization analysis. The P2X7 mRNA level in the P2X7 shRNA-
injected DG and in the negative control injected DG of each slice was evaluated. 21-
22% of mRNA down-regulation with the P2X7-shRNA vector compared to the QNSC-
shRNA vector (p-value ≤0.001; ANOVA) was detected in the AAV injected animals. In 
the Ad5 group, a trend for P2X7 mRNA decrease in the P2X7-shRNA injected DG 
compared with the QNSC-shRNA injected hemisphere was observed (Fig. 40, 41).  
b a 
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Fig. 40. a: P2X7 mRNA detection in dorsal rat hippocampus 4w after AAV2/6-shRNA injection in the 
sample 4 (left: AAV-QNSCshRNA and right: AAV-P2X7shRNA). b: P2X7 mRNA detection in dorsal 
rat hippocampus 2w after Ad5-shRNA injection in the sample 3 (left: Ad5-QNSCshRNA and right: Ad5-
P2X7shRNA). The arrows indicate the DG area. 
 
 
 
 
Fig. 41. a: P2X7 mRNA quantification in dorsal rat hippocampus 4w after AAV2/6-shRNA injection (n= 
8 slices). b: P2X7 mRNA detection in dorsal rat hippocampus 2w after Ad5-shRNA injection (n= 8 
slices). 1 animal per group died prior to the analysis. 
 
In particular in two of the five animals analyzed a P2X7 mRNA decrease was not 
observed. This was probably caused by a lower amount of virus being injected due to 
glass needle blocking. In fact in these 2 animals a lower level of GFP expression was 
observed but it was not possible to accurately quantify it since the brain slices analyzed 
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were frozen and the tissue morphology was not well preserved. Therefore it was not 
possible to normalize the P2X7 mRNA level for the amount of virus injected as 
previously done in the TaqMan analysis. The in situ hybridization experiment was 
repeated with similar results.  
In conclusion, in vivo studies indicate the ability of the AAV- and Ad-shRNA 
vectors to suppress the target mRNA expression in vivo, in rat hippocampus. Further 
studies will be necessary to demonstrate the functional suppression of P2X7 receptor 
after viral vector injection in vivo and associated behavioural effects. 
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5. DISCUSSION AND CONCLUSIONS 
 
As discussed in the introduction, P2X receptors are ATP-gated cation channels 
permeable to sodium, potassium and calcium, which mediate fast excitatory synaptic 
responses both on autonomic nerve endings and on a limited population of neurons in 
the CNS. In neurons, both somatodendritically and presynaptically, P2X receptors are 
involved in the modulation of neurotransmitter release and activation of multiple 
intracellular signalling pathways. In addition, the P2X7 receptor is expressed on glial 
cells in many regions of the brain where it plays a role in the release of cytokines. 
Experimental data suggest an involvement of the P2X7 receptor, and of the P2X2 and 
P2X4 receptors to a less extent, in psychiatric disorders, including both unipolar and 
bipolar depression. Expression of P2X7 mRNA is decreased by stress in rodents and 
this effect is prevented by treatment with the antidepressant paroxetine (Barden et al., 
2004). In addition, selectively decreasing P2X7 expression in the hippocampus of mice 
with an antisense RNA leads to increased immobility in the forced swimming test, a 
screen used to predict clinical efficacy of antidepressants. Furthermore, a genetic 
association of the region containing the P2X7 gene with depression was found (Barden 
et al., 2006). This region additionally contains the P2X2 and P2X4 genes, which may 
also play a role in the etiology of depression. 
To better understand the functional role of P2X2, P2X4 and P2X7 receptors in 
rat brain and their involvement in the etiology of depression, RNA interference has been 
used to down-regulate their expression. This approach has important advantages over 
previous techniques used to manipulate gene expression. Transgenic and knockout mice 
are limited by developmental effects, genetic compensation, and a lack of regional 
specificity. These problems can be overcome by conditional transgenic mice to restrict 
effects in a spatial-temporal manner. However, generating these animals is difficult and 
time-consuming. Finally, the injection of antisense oligonucleotides into specific brain 
regions is complicated by their rapid in vivo degradation. Even if chemically modified 
to increase their stability, repeated infusion of oligonucleotides is required to achieve 
long-term in vivo suppression of a target protein. Recently, RNA interference, a 
sequence-specific suppression of mRNA expression by stretches of homologous double-
stranded RNA, has been shown to function across a wide range of organisms, including 
mammals (Mittal, 2004). Moreover, in addition to its use as a tool for biologists, short 
 101
double stranded RNA is thought to play an important role in the regulation of gene 
expression during development (Bartel, 2004).  
RNAi has been widely used to explore the patho-physiology of neuropsychiatric 
diseases. Several RNAi approaches can be used to reduce gene expression in 
mammalian brain. As described by Thakker and colleagues, target gene was suppressed 
by siRNA infusion into the dorsal third ventricle via osmotic minipumps (Thakker et al., 
2005). They achieved a widespread suppression of the serotonin transporter gene after a 
2-week siRNA infusion. This decrease in mRNA level translated into a widespread 
reduction specifically in the levels of SERT protein in the brain and in an 
antidepressant-like behaviour measured in the mouse forced swim test. This behavioural 
effect was identical to the response obtained from mice that received a selective SERT 
inhibitor. These results therefore demonstrated the possibility to achieve widespread 
gene knowkdown in the brain with i.c.v. infusions of siRNA to produce a behavioural 
phenotype. In any event, a large amount of chemically modified siRNA was required. 
An alternative method of siRNA delivery into the brain is injection of shRNA-viral 
vectors. Babcock and colleagues (2005) targeted the hippocampal A-Ca2+/calmodulin-
dependent protein kinase II (A-CaMKII) which has been implicated in spatial learning, 
neuronal plasticity, epilepsy, and cerebral ischemia. They designed an AAV vector to 
express a shRNA targeting A-CaMKII driven from the U6 promoter (AAV-shCAM) 
and the marker protein GFP. The AAV-shCAM vector was microinfused into the rat 
hippocampus and 4 weeks later A-CaMKII and GFP expression and behaviour were 
studied. A-CaMKII protein was significantly reduced by shRNA treatment. This 
suppression of A-CaMKII was associated with changes in exploratory behaviour in the 
open field task and impaired learning in the Morris water maze (Babcock et al., 2005). 
These results demonstrate the efficacy of virally-based siRNA constructs targeting 
neuronal protein expression in the brain.  
The final goal of this project was to produce a long term down regulation of P2X 
receptor expression in rat hippocampus in order to investigate behavioral effects. This 
required long term expression of the siRNA sequences in vivo by using shRNA-
expressing vectors. To overcome the problem of poor transfection efficiency of 
mammalian cells with plasmid-based vectors, viral vectors were generated. Previous in 
house studies suggested that adeno-associated virus and adenovirus preferentially infect 
neurons and glial cells in vitro, respectively. Since the target cells of this study are 
hippocampal neuron and glia, AAV and AdV vectors were chosen to deliver the shRNA 
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cassettes. AdV and AAV possess advantages over other viral vectors such as the ability 
to infect both dividing and non dividing cells and to persist episomally, increasing the 
chance for long term expression and avoiding risks related to viral integration into the 
host cell genome (Walther and Stein, 2000). Moreover these vectors, in particular the 
AAV, can be safely manipulated and present a low level of toxicity and immunogenity.  
In order to develop the shRNA-expressing viral vectors, several siRNA 
sequences targeting each gene were designed and validated by means of transfection in 
the rat pheochromocytoma cell lines PC12 and PC12NS1 and in rat astrocytes using a 
surfactant as delivery agent. Both PC12 and PC12NS1 cells express the P2XR genes. 
Astrocytes were chosen since both P2X4 and P2X7 receptors are endogenously 
expressed in these primary cells. Active and specific siRNA sequences, able to suppress 
target mRNA expression, were identified. Interestingly siRNA-mediated gene 
suppression was not measured in the PC12NS1 cells by TaqMan analysis, while the 
same siRNA sequences were effective in the parental cell line PC12. These results 
suggest potential differences in the RNAi machinery of the two cell types. The results 
also demonstrate the need to validate siRNA sequences in several cell types. From the 
selected siRNA sequences, the U6-shRNA cassettes were produced and cloned into a 
pENTR plasmid. These plasmids were then screened for their ability to down-regulate 
the expression level of the target receptor by transfecting astrocytes and recombinant 
and co-transfected cell lines. Plasmid transfection in astrocytes was not achieved even 
though several delivery agents and several experimental conditions were tested. This 
reflects the general low transfection efficiency in primary neuronal cultures using 
surfactants. Therefore DNA “nucleofection” was used for shRNA-plasmid delivery into 
astrocytes. Up to 100% mRNA suppression was achieved in co-transfected cell lines 
while a maximum of 70% of mRNA suppression was obtained in recombinant cell lines 
and astrocytes. The lower level of P2XR suppression in astrocytes can be explained by 
the higher resistance of these primary cells to exogenous DNA transfection while 
recombinant cell lines were more sensitive than normal cell lines to the transfection 
agents. The specificity of the shRNA-vectors was also tested. In fact a problem often 
encountered with siRNA-mediated gene suppression is down-regulation of non-related 
genes. Commercial antibodies were tested and selected for evaluation of protein levels 
after shRNA-plasmid delivery. Even if several experimental conditions were tested, 
they were not found to be reliable for a quantitative analysis where the quality of the 
signal is critical to obtain statistically significant results. This suggests that, depending 
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on the antibodies available, Western blots is not the optimal method for quantification 
of protein suppression and that a functional assay, if available, could be more reliable to 
evaluate target protein knockdown. 
Finally, the shRNA cassettes were cloned into viral vectors. Several AAV2-
based shRNA vectors were produced for the three different P2X receptors. AAV2- 
vectors were selected since different experimental reports demonstrated that they can 
deliver the shRNA cassette to neurons both in vitro and in vivo and can produce a long-
lasting, highly efficient and specific down-regulation of gene expression (Michael et al., 
2005). The serotype AAV6 was chosen for vector packaging because it infected neurons 
in vitro at the highest levels among the serotypes available in house. Since P2X7 is also 
expressed in glial cells, two Ad5-shRNA vectors targeting P2X7 were produced. GFP 
was co-expressed in the AAV-shRNA vectors to measure the level of infection. An Ad5 
vector expressing GFP was also produced since the Ad5-shRNA vectors do not express 
a marker gene. These viral vectors were initially screened for their ability to infect 
hippocampal neurons (AAV2/6) and astrocytes (Ad5) and to suppress target gene 
expression in vitro.   
An Ad5 vector suppressing P2X7 mRNA expression without affecting P2X4 
mRNA levels in cultured rat astrocytes was identified. A maximum of 80% mRNA 
suppression compared to control was observed. Moreover a high level of astrocyte 
infection, estimated at around 80%, was measured after AdV-GFP infection without 
evident signs of toxicity. Analogous suppression of P2X7 protein was not confirmed, 
because the commercially available antibody was not accurate enough to quantify the 
specific protein band in a Western blot analysis, even though several experimental 
conditions were attempted in order to optimize protein detection. Preliminary data 
demonstrated a decrease in P2X7 function in Ad5-P2X7-4 infected microglial cells 
compared to control, measured as agonist-induced IL-1ß release after LPS treatment. 
There was a statistically significant functional suppression but a certain level of toxicity 
in the cells was detected after Ad5 infection.  
AAV2/6 vectors suppressing P2X2, P2X4 and P2X7 mRNA expression in 
cultured rat hippocampal neurons were generated. A high level of target gene 
suppression (a maximum of 90% suppression compared to the control) was measured 
by TaqMan analysis without non-specific effects. 80-90% hippocampal neuronal 
infection was observed using GFP fluorescence, with a certain level of toxicity only 
after a prolonged viral exposure. No reliable data for protein suppression were obtained 
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from Western blot analyses and no functional data could be generated due to lack of 
assays in house.  
One active and specific AAV-shRNA viral vector for each receptor and one 
active and specific AdV-shRNA vector targeting P2X7 were selected from these in vitro 
experiments for in vivo investigation. Since a series of preclinical and genetic data 
suggested a role of P2X7 in the etiology of depression, in vivo work was focused on this 
gene. A viral vector injection procedure in rat brain was optimized in order to achieve 
the maximum cell infection with AdV and AAV vectors, without causing anatomical 
damage. For this procedure, home made glass needles were used since in house studies 
demonstrated their ability to induce a negligible amount of anatomical disorganization 
and inflammation compared to commercially available steel needles.  
The presence of the Ad5 and AAV viral vectors in the injected brain area were 
demonstrated. The viruses were injected into the dentate gyrus of rat hippocampus since 
both P2X7 mRNA and protein are reported to be expressed in this region and because 
hippocampus is believed to play a key role in the patho-physiology of psychiatric 
disorders. AAV2/6 vectors were detected by GFP expression through direct 
fluorescence visualization and IHC analysis. After AAV injection into the dorsal DG, 
GFP was detected both in the granular cell layer and in the polymorphic layer. 
Moreover GFP expression was detected in the surrounding area such as the pyramidal 
cell layer in CA1, CA2 and CA3 regions and the mossy fibers, demonstrating the ability 
of AAV2/6 to infect both granular and pyramidal neurons in vivo and of GFP protein to 
travel anterogradely within neurons, as previously described by Mandel and Muzyczka 
for the AAV2/1 and AAV2/5 vectors (Mandel and Muzyczka, 2004). In contrast, no 
staining in the controlateral non-injected hippocampus was observed, indicating that this 
serotype does not undergo transport to distal sites or retrograde transport as seen for 
other serotypes such as the AAV2/5 and AAV2/9 (Mandel and Muzyczka, 2004 and 
Cearley and Wolfe, 2006). From a co-localization study with the neuronal marker 
MAP2, GFP was detected in neurons both in cell bodies and in projections. Widespread 
(~1-2 mm) rostro-caudal expression of GFP in the hippocampus 28 days following 
AAV microinfusion was observed, consistent with literature reports (see Babcock et al., 
2005). Despite this encouraging evidence, subsequent in house experiments 
(unpublished) demonstrated that the AAV6 was not the best serotype to achieve the 
highest neuronal infection in vivo. In these studies other serotypes, in particular AAV8 
and AAV9 produced wider infection of rat hippocampus after intracranial injection 
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compared to the AAV6 (data not shown). Recently Klein and colleagues (2007) 
reported that the AAV8 and AAV9 vectors produced a higher level of transduced cells 
compared to other AAV serotypes after microinjection in rat hippocampus. In addition 
the authors showed that the method of viral vector purification can influence the 
transduction pattern as well as the results when comparing serotype strengths. Similar 
studies reported high transduction efficiency with the AAV8, AAV9 and AAV10 
vectors in rat brain (Cearley and Wolfe, 2006).  
The expression of GFP in the dorsal and ventral hippocampus 2 and 4 weeks after 
Ad5-GFP viral vector injection was also shown. IHC verified that GFP expression was 
concentrated in the injection site, within the dentate gyrus, with undetectable diffusion 
into the surrounding area. The staining was observed for roughly 0.8-1 mm around the 
injection area in the rostro-caudal axis. The majority of the cells stained were astrocytes, 
with a minority showing neuronal morphology, confirming previous in vitro results. 
From a qualitative analysis, neither astrocytosis nor mechanical damage was observed 
in the injected area, thus excluding the presence of inflammation induced by the virus or 
by the injection method. The intensity of GFP fluorescence, GFP IHC and TaqMan 
quantification of the Ad5 viral genome demonstrated decreasing levels of viral vector in 
glia over time. Since the viral vector does not integrate into the nuclear DNA, these 
results suggest that the viral genome was diluted, possibly through replication of glial 
cells. In fact it is now well established that astrocytes undergo cell division even under 
basal conditions and that the hippocampus of normal adult mammalian brain is a region 
of proliferation of neural progenitor cells (see for example Chirumamilla et al., 2002). A 
difference in the amount of virus measured in each animal was detected by TaqMan 
quantification of the Ad5 viral genome, probably due to the infusion technique and 
potential obstruction of the injection needles due to the small diameter of their tip and 
opposite pressure in the tissue.  
TaqMan analysis was initially chosen to measure target mRNA after viral vector 
injection. Following Ad5-shRNA viral vector injection in both dorsal and ventral DG, 
no significant variations in P2X7 mRNA expression were detected in the whole 
hippocampus, even after normalization for the amount of viral genome detected in each 
sample. Possibly the amount of virus injected into the whole hippocampus was not 
sufficient to suppress P2X7 expression, since viral numbers appeared to be diluted. 
Most likely TaqMan analysis of the whole hippocampus was not sensitive enough to 
detect a decrease in mRNA expression occurring in a limited part of it. In fact the 
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shRNA-viral vector was injected only in a restricted region of the hippocampus (dorsal 
and ventral DG) while the whole hippocampus was processed for TaqMan analysis with 
a probable dilution effect. Indeed from GFP fluorescence and GFP IHC the virus was 
detected only in a small region of the whole tissue analyzed. To overcome this problem, 
a possibility is to specifically isolate the anatomical region corresponding to the injected 
area, for example through isolation of the apical and caudal regions of the hippocampus. 
Other methods (not available in house) that can be used for dissection of the injected 
area are tissue micro-punch dissection and laser-capture microdissection (LCM). This 
last technique was used by Hommel and colleagues to remove the AAV-shRNA 
infected cells in the ventral tegmental area which were identified for removal by 
detection of GFP expression and were subsequently analyzed for target gene 
suppression. Real-time RT-PCR analysis revealed a significant decrease of the target 
mRNA in the neurons infected with the targeting AAV-shRNA vector compared with 
neurons infected with the control shRNA vector isolated by LCM (Hommel et al., 
2003). The number of animals used in this in vivo experiment (4 per group) was not 
ideal for a quantitative study, because 6 to 8 replicates are normally needed for TaqMan 
analysis. Since P2X7 receptor expression is activated in glia after inflammatory events, 
the viral vector injection could have induced an inflammatory response in the injected 
area and therefore a P2X7 mRNA increase, thus preventing the possibility to measure 
target gene suppression. This hypothesis was not confirmed since GFAP staining 
observed in the injected and not-injected hemisphere was qualitatively similar, 
excluding the presence of inflammatory astrogliosis in the injected area. Regarding the 
time points analyzed, 2 weeks or less, rather than 4 weeks after Ad-shRNA injection 
was found to be a better time point for gene suppression detection. In fact, Xia and 
colleagues (2002) reported target gene suppression already 4 days after Ad-shRNA 
injection in rat brain, and Chen and colleagues (2006) measured a time-related decrease 
in gene suppression, in particular 20 days post-injection compared to 10 days.  
After this first experiment, another in vivo study with both AdV and AAV 
injection was performed. A different injection protocol was optimized in order to 
achieve a higher infusion of the virus into rat hippocampus through injection of the 
virus at 2 different depths of infusion. Moreover for this study in situ hybridization was 
used to evaluate mRNA suppression. With this technique it is possible to detect the 
mRNA levels directly within the anatomical region of interest, easily permitting 
detection of mRNA suppression after shRNA-vector delivery. Initially a colorimetric in 
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situ hybridization analysis with a digoxigenin labelled P2X7 riboprobe was tried. This 
method was chosen over the radioactive method since it permits avoiding the special 
precautions needed for the use, handling and safe disposal of radionucleotides even 
though it could present several disadvantages over radioactive labeling such as the 
lower level of sensitivity, the impossibility to perform a quantitative analysis and the 
frequent non-specific staining (see Wilkinson et al. 1999). Even though experimental 
conditions such as hybridization, post-hybridization temperature and time, were altered, 
it was not possible to reduce the background level. In addition, a high damage level of 
the tissue was observed after analysis, due to the experimental conditions used. 
Subsequently, a radioactive in situ hybridization analysis with a P2X7 oligonucleotide 
was performed since it is possible to measure even very low levels of gene suppression 
and to carry out a quantitative analysis. 20-22% of P2X7 mRNA down-regulation in the 
AAV-shRNA-P2X7 injected dentate gyrus compared to the control QNSC-shRNA 
injected DG was measured. The P2X7 mRNA suppression resulted statistically 
significant (p-value ≤0.001). This decrease in mRNA level is much lower compared to 
that measured after cell infection in vitro. RNAi-mediated gene silencing in vivo is 
expected to be less than that which can be obtained in vitro due to the higher difficulty 
of siRNA delivery in vivo. This is particularly true when the target tissue is brain. First 
of all this tissue is limited by the BBB that restricts the passive entry of materials from 
the peripheral circulation. If directly injected into the brain, the shRNA-viral vectors can 
be diluted in non-targeted regions or inactivated by endonucleases. Moreover, when 
using needles with limited outer diameter for the microinjection, the viral diffusion into 
the target area is hindered by high opposing pressure of the tissue and the possibility of 
clogging the needle. This limited mRNA suppression could also be dependent upon the 
AAV serotype used as shown following viral vector delivery of GFP. In any case as 
reported in the literature, a limited decrease in the mRNA level could still be associated 
with a functional suppression and a behavioral effect (Thakker et al., 2005 and Hommel 
et al., 2003). For example Hommel and colleagues measured ≈ 23% of target gene 
mRNA suppression by RT-PCR after AAV-shRNA injection into the ventral tegmental 
area. This localized gene knockdown was associated with a statistically significant 
behavioral change. This seems to suggest that the reduction in the P2X7 mRNA in the 
DG injected with the targeting AAV shRNA vector is associated with a reduction in the 
P2X7 receptor function.  
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In the Ad5 group, a trend for P2X7 mRNA down-regulation in the P2X7-shRNA 
injected DG was observed, but it was not statistically significant. The number of 
animals used in this study was not optimal for a statistical analysis. In particular in 2 out 
of the 5 animals analyzed a decrease in mRNA level was not observed. This could be 
dependent on a lower amount of viral vector injected due to the obstruction of the glass 
needle. In fact with in situ hybridization it was not possible to accurately quantify the 
amount of virus injected, as previously done with TaqMan. The amount of virus 
injected was qualitatively determined by GFP expression since the AAV-shRNA 
vectors expressed the GFP protein and the AdV-shRNA vector was co-injected with the 
AdV-GFP vector. From a qualitative analysis a difference in the GFP staining in these 2 
animals was observed but it was not possible to determine it accurately and to normalize 
the P2X7 mRNA level for the amount of viral genome injected. Since the brain slices 
were frozen for the radioactive in situ hybridization, the morphology of the slices 
analyzed was not well defined. Therefore it was not possible to quantify GFP 
expression. 
The present study demonstrates that microinfusion of AAV-shRNA-P2X7 in the 
dentate gyrus resulted in a small but statistically significant suppression of rat 
hippocampal P2X7 mRNA expression, while a similar trend even if not statistically 
significant was obtained with the AdV-shRNA injection. The AAV serotype used in this 
study may not be the best one to achieve neuron infection in vivo, even though an 
elevated infection of hippocampal neurons was obtained in vitro. Moreover it was 
demonstrated that the glass needle injection method was able to infuse viral vectors into 
restricted brain areas without inducing anatomical damage and inflammation. A certain 
level of variation in the amount of virus injected was observed in some animals due to 
the extremely small external diameter of the needle tip and the possibility to clog it. In 
any case this problem could be overcome though quantification of the virus injected in 
each sample and normalization of the target mRNA or protein level for the amount of 
virus detected. Future studies are needed to evaluate functional P2X7 suppression ex 
vivo with the P2X7-shRNA vectors, such as measuring channel activity after shRNA-
vector injection. In addition, a phenotypic effect in a behavioral test such as the forced 
swimming test could be evaluated.  
In conclusion, in this project viral vector-mediated RNA interference was 
explored for the suppression of target genes both in cultured cells and in the rat brain. 
Active and specific AAV- and AdV-shRNA vectors able to suppress target gene 
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expression in neuronal cells were generated and validated both in vitro and in vivo. 
Unfortunately it was not possible to measure the level of the target protein after shRNA 
vector delivery either in vitro or in vivo since the commercially available antibodies did 
not result in a clear stain in the Western blot analysis. Phenotypical assays measuring a 
decrease in the activity of the target gene after shRNA-vector delivery are ideal for 
siRNA validation, but are not always available depending on the target gene function. In 
this study a functional assay for the P2X7 receptor in microglial cells was set up that 
allowed detecting a significant P2X7 functional decrease in the cells infected with the 
targeting Ad5-shRNA vector compared to the control vector. On the other hand, no 
functional assays were available in house to measure P2X receptors function in neurons. 
Compared to other approaches available, such as siRNA infusion into the brain via 
osmotic minipumps, this method requires more time for the development, production 
and validation of the shRNA-viral vectors in vitro prior to in vivo delivery. Nonetheless, 
with this method it is possible to achieve a long term suppression of gene expression in 
neuronal cells since the viral vector, in particular the AAV vector, is expressed after an 
extended period. In fact the transduction volume after intracranial injection with the 
AAV vectors was shown to be constant two weeks post-injection compared with two 
months post-injection for several serotypes, indicating that transgene expression 
remained invariable over a long period of time (Taymans et al., 2006). Moreover with 
this method it is possible to obtain a localized viral vector infection and siRNA 
expression allowing the investigation of the effects of target gene suppression in the 
specific area of interest. Some technical conclusions can be drawn by this study. The 
detection method chosen for gene knockdown evaluation must be selected 
appropriately, since it could be difficult to detect gene suppression occurring in the 
limited area of viral vector injection. Moreover the protocol of injection and the amount 
and serotype of virus used for the delivery of the shRNA cassette play a key role in the 
success of the overall experiment.  
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